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Abstract 
Novel formulations of a poorly soluble drug using the extrusion process 
Chaitrali S Kulkarni 
Key words: HME, thermolabile drug: artemisinin, Soluplus®, polymorphism, 
stability.  
Hot melt extrusion has attracted recent interest from the pharmaceutical 
industry and academia as an innovative drug delivery technology. This novel 
technique has been shown to be a viable and robust method for preparing 
different drug delivery systems including pellets, implants, tablets, capsules 
and granules. The aim of this research was to understand hot melt extrusion 
processing and explore its pharmaceutical applications. Two applications of 
hot melt extrusion (HME) have been investigated to improve the properties of 
poorly soluble thermolabile drugs; polymeric solid dispersions and solid state 
polymorphic transformation.  
HME is a solvent free, continuous and readily scalable technique which is 
increasingly being considered as a viable alternative to conventionally used 
batch techniques. However, the high temperature and shear forces imparted 
by the extrusion process can limit its applications with heat sensitive active 
pharmaceutical ingredients (APIs). Artemisinin was selected as a model drug 
which being thermolabile in nature and possesses processing challenges to 
processing HME. A low Tg amphiphillic copolymer, Soluplus® was selected 
as a matrix material. Drug-polymer compatibility was studied using rotational 
rheometry and thermal characterisation. The drug was found to be 
completely dissolved within the polymer, although some discolouration of the 
mixture was observed, indicating degradation of the API. The addition of a 
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small percentage of citric acid to the formulation was found to prevent this 
degradation by increasing the pH. The dissolution profile of the formulation 
was approximately five times higher compared to that of the pure drug. The 
pharmacokinetic study was carried out using Albino rats to calculate 
bioavailability. The area under plasma concentration time curve (AUC0-24hr) 
and peak plasma concentration (Cmax) were four times higher for the 
prepared solid dispersion compared to that of pure artemisinin. Extruded 
solid dispersions were found to be amorphous in nature and maintained 
stability for 2 years.      
A second route to improving the solubility of poorly soluble APIs was also 
investigated. It was found that under carefully controlled conditions, high 
temperature extrusion (HTE) could be used to achieve polymorphic 
transformation with a number of APIs. This solvent-free continuous process 
was demonstrated with artemisinin, piracetam, carbamazepine and 
chlorpropamide.  Artemisinin was used as a detailed case study of stability, 
solvent mediated transformation and mechanism of polymrophic 
transformation during extrusion, using computational modelling and model 
shear flows. At high temperature, phase transformation from orthorhombic to 
triclinic crystals was found to occur via the vapour phase. Under mechanical 
stress the crystalline structure was disrupted, leading to new surfaces being 
continuously formed and exposed to high temperatures; thus accelerating 
the transformation process. Polymorphic transformation during HTE was 
found to comprise three stages; i) preheating and conveying; ii) vapour 
phase transformation and size reduction and iii) continuous transformation 
and agglomeration. The triclinic form showed four times greater dissolution 
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rate as compared to the orthorhombic form. The triclinic form showed two 
fold increase in bioavailability in Albino rats.  
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1. Introduction 
Hot Melt Extrusion (HME) has attracted recent interest from the 
pharmaceutical industry and academia as a technology which can enable 
innovative drug delivery routes. The aim of this research was to explore 
novel applications of HME to achieve stabilised systems of poorly water 
soluble Active Pharmaceutical Ingredients (APIs) using polymeric solid 
dispersions and continuous polymorphic transformation. Figure 1.1 shows 
advantages of HME in the pharmaceutical industry.  
 
Figure 1.1 Advantages of HME in the Pharmaceutical Industry 
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The pharmaceutical industry shares a secret that, although it discovers many 
advanced and innovative drugs, its manufacturing technologies lag behind 
those of the detergent and potato chip industries. However, there is now a 
drive to improve and modernise production methodologies. The US Food 
and Drug Administration (FDA) has actively encouraged the pharmaceutical 
industry to take up manufacturing innovation in order to improve quality (Leila 
et al., 2003). Many new processing techniques have been introduced to the 
pharmaceutical industry as a result, to improve the effectiveness and 
efficiency of all steps of the manufacturing process, including design, control 
and quality assurance.  
Hot Melt Extrusion (HME) is a green manufacturing approach which has 
recently attracted interest from the pharmaceutical industry and academia as 
an innovative manufacturing process to produce new drug delivery systems. 
This novel technique has been shown to be a viable and robust method for 
preparing different drug delivery systems including pellets, implants, tablets, 
capsules and granules (Crowley et al., 2007). HME offers many advantages 
over conventional pharmaceutical processing techniques. Typically, in HME, 
no solvent is used and fewer operation steps are involved. The hazardous 
nature of most organic solvents and the presence of residual solvents after 
drying in conventional processes may be problematic and costly.  
Complicated processing conditions and disposal of the associated waste can 
create significant environmental concerns regarding these manufacturing 
techniques. As a result, alternative technologies are sought by the 
pharmaceutical industry to overcome some of these challenges 
(Maniruzzaman et al., 2012). A key advantage of HME is that it can be 
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achieved through a single continuous processing step which makes it 
economical. Continuous manufacturing to produce chemicals, APIs and final 
dosage forms is gaining widespread attention. Although the potential 
advantages over traditional batch processes have been widely reported, 
continuous processes are only slowly being implemented (Poechlauer et al., 
2012). In addition, the US FDA has emphasised the need for process 
innovation through better process understanding by adapting Process 
Analytical Technology (PAT). HME is well suited to meet the proposed FDA 
guidelines for PAT in the design, analysis and control of the extrusion 
process by continuous monitoring. 
1.1. Research objectives and approach  
The main aim of this research was to explore novel pharmaceutical 
applications of hot melt extrusion technology. The challenges and 
opportunities stemming from poorly soluble molecules for oral delivery have 
been explored and considered in the wider context of how the 
pharmaceutical industry is adopting unconventional technologies to bring 
new drugs into the market. Figure 1.2 indicates pharmaceutical applications 
of HME technology.  
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Figure 1.2 Applications of HME technology 
 
Specific objectives of this research were:  
 
 To investigate and address challenges in the application of HME  for 
processing  solid dispersions containing thermolabile drugs 
 
 To explore the application of HME to cause polymorphic 
transformation during processing 
 
 To develop a mechanistic understanding of polymorphic 
transformation during extrusion  
 
 To investigate solvent mediated polymorphic transformation  
 
 To confirm the biopharmaceutical performance of the amorphous and 
metastable polymorphic states achieved by extrusion  
Schematic presentation of the research work has been shown in figure 1.3.  
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Figure 1.3 A schematic representation of the research structure 
1.2. Thesis outline 
Chapter 2 provides a background and is divided into three major sections; 
firstly the concept of a solid dispersion is presented, including a description 
of its types and different methods of preparation. The second section 
describes the basics of polymorphs and their significance to the 
pharmaceutical industry. The final section provides an introduction to the hot 
melt extrusion technique, its principles, pharmaceutical applications, 
advantages and limitations.  
Chapter 3 describes details of the materials and methods adopted in the 
present work and has been divided into two major sections; solid dispersions 
of artemisinin and polymorphic transformation using HME. The solid 
dispersion section provides details of the HME methodology, composition 
variables and characterisation including in-vitro and in-vivo evaluations of the 
HME 
Thermolabile  
APIs 
Artemisinin 
Stabilised 
Amorphous  
Form 
Characterisation 
Polymorphic 
Transformation 
Artemisinin 
Characterisation 
Stability 
Solvent 
Mediated 
Transformation  
Piracetam Chlorpropamide Carbamazepine 
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optimised artemisinin – Soluplus® systems. The section about polymorphic 
transformation using HME describes the optimisation of process parameters, 
characterisation procedures, experiments performed to understand the 
mechanism, stability of the polymorph, computational techniques used and 
bioavailability studies.   
Chapter 4 contains the results and discussion of artemisinin solid dispersion 
studies. An important outcome of this work related to avoiding artemisinin 
degradation during extrusion by selecting a stabiliser, thus achieving four 
times more bioavailability compared to the crystalline drug.    
Chapter 5 explains how a stabilised triclinic form of artemisinin was 
generated and investigates the crystal transformation of other drugs. A major 
focus of this chapter is to explain the mechanism of polymorphic 
transformation of artemisinin using results from a shear cell and other 
techniques. Another important aspect is the mechanistic understanding of 
stability of the triclinic form and the role of solvents in destabilisation. Chapter 
5 also details a bioavailability study and polymorphic transformation studies 
on other model molecules including chlorpropamide, piracetam and 
carbamazepine.  
Chapter 6 provides an overall summary and conclusions of the work 
presented in this thesis and the scope for future work.  
Chapter 7 contains references to published work cited within the thesis.   
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2. Background 
This chapter includes introduction to solid dispersion, polymorphs and hot 
melt extrusion technique. A schematic presentation of the chapter is shown 
in figure 2.1.  
 
Figure 2.1 A schematic presentation of background 
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2.1. Introduction 
A significant number of APIs in the market have been confirmed to have low 
solubility and bioavailability. Although different approaches such as 
solubilisation, size reduction and complexation using cyclodextrin have been 
proposed to increase solubility and oral absorption of such drugs, these 
techniques have not solved the problems of many drugs (Sharma et al., 
2010). Drug solubilisation in either aqueous or organic medium using 
surfactants or co-solvents gives liquid formulations which are generally 
objectionable from a commercialisation and patient point of view. Reduced 
particle size of the drug may be considered commonly to improve dissolution 
rate. Various techniques are available to obtain fine particles including 
grinding, controlled precipitation by changing solvent and temperature, ball 
milling and conventional trituration (Goldberg et al., 1966). A faster 
dissolution rate may not be achieved in many cases by particle size 
reduction because of strong van der Waals forces between non polar 
molecules. The solvent method is a better option to achieve fine particle size 
but it is not applicable for many drugs due to the use of toxic solvents 
(Muhammad et al., 2001). Also, the application of fine powders in dosage 
forms may not be feasible due to low wettability and handling difficulties.  
In dosage form design, it is important to understand pharmaceutical 
techniques to achieve enhanced dissolution, absorption and efficacy of APIs. 
Therefore, the study of method of preparation, selection of suitable carrier, 
analysis of physical properties will be a vital approach in effective and 
practical dosage form development. 
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2.2. Solid state chemistry 
Solid state chemistry deals with study of the synthesis, structure and 
properties of solid state materials. It has a strong connection between solid 
state physics, mineralogy, crystallography, ceramics, metallurgy, 
thermodynamics, material science and electronics with an aim of the 
synthesis of novel materials and their characterisation. There have been 
major advances in solid state and materials chemistry in the last two 
decades that are an integral part of life (Janse, 2002; Disalvo, 2000 and 
Bishop et al., 1996). The study of solid-state chemistry of drugs covers many 
scientific disciplines within the pharmaceutical industry from discovery to 
successful marketing. It is known that an understanding of the molecular 
structure of the solid state can lead to better design and control of drug 
performance. The isolation, identification and characterisation of a new 
molecule by advanced techniques is one of the most active areas of modern 
solid state chemistry (Kanatzidis et al., 2007; Hilfiker et al., 2007; Byrn et al., 
1999 and Braga et al., 2010). The aim of researchers in the field of solid 
state pharmaceutical chemistry is to provide each drug in a solid state which 
has optimum properties for any given application (Byrn et al., 1994).  
2.3. Solid forms 
The pharmaceutical industry invests considerable resources in identifying 
novel APIs with desirable physicochemical properties which could be later 
formulated into drugs. Nevertheless, to be considered for commercial use, an 
API's physicochemical properties, which are generally dependent upon 
dosage form, must be controllable and must adhere to the guidelines set up 
by the regulatory authorities e.g. US FDA. APIs are commonly formulated in 
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the solid state such as tablets, capsules, granules, powder etc. because 
chemical stability is better in this form compared to alternatives (Morissette et 
al., 2004). Moreover, solid state formulations offer more practical means of 
processing, handling and packaging the APIs and they are the preferred 
choice by most patients because of their easy uptake in the body.  An API 
can exist in a number of solid forms such as amorphous, polymorphs, 
solvates, salts and co-crystals (as shown in figure 2.2). Each form may 
display its own unique physicochemical properties of pharmaceutical 
importance including mechanical, surface, physical, thermal and chemical 
properties, that can profoundly affect bioavailability, solubility, hygroscopicity, 
stability, processability and other characteristics of the drug (Byrn et al., 
1995). Such diversity offers the opportunity of tuning key physiochemical 
properties of the pharmaceutical product without compromising the 
physiological activity of the API as the molecular structure is preserved.  
 
Figure 2.2 Classification of solid forms (Byrn et al., 1995) 
Solid 
Amorphous Crystalline 
Single component  
Polymorph 
Multicomponent 
Salt 
Hydrate / 
Solvate 
Co-crystal 
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It has been estimated that more than 40% of APIs suffer from a 
bioavailability issue because of their low water solubility. Due to the advent of 
computational chemistry and the importance of lipophilic receptors, this 
percentage is expected to increase (Kerns et al., 2001). This is a major 
drawback for drug formulations because many new potential drugs fail in the 
formulation stage. The formulation of such compounds for oral delivery 
exhibits one of the most common and difficult challenges to formulation 
scientists. More than 80% of marketed formulations are in the solid form and 
90% of these are crystalline in nature. An enhancement of the solubility of a 
drug may improve its bioavailability. Identifying the optimum form of an API is 
scientifically and clinically preferable (Byrn et al., 1999). Research over the 
past decade has changed the paradigm of ‘one molecule, one crystal’ to ‘one 
molecule, many crystals and therefore many properties’ (Braga et al., 2010). 
This is shown schematically in figure 2.3.   
 
Figure 2.3 Arrangement of molecules in different structures 
Experimental efforts and creative approaches can reveal new forms with 
advantageous properties. The exploration of crystal forms can have a 
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significant impact on applied and fundamental science because the different 
crystal forms may show different physicochemical properties. The range of 
crystalline forms that are possible for an API are shown is figure 2.4.  
 
Figure 2.4 Possible solid forms for an API 
Generally, for an API which has low water solubility; it may be preferable to 
use an amorphous or more soluble form. The amorphous form consists of 
disordered arrangement of molecules which do not form a distinguishable 
crystal lattice. The amorphous form has a stability issue but this can be 
stabilised by forming a solid dispersion.  
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2.4. Solid dispersions 
Currently, more than 60% of drug candidates suffer from poor water 
solubility. This results in potential products not reaching the market. Over the 
last 20-30 years solid dispersion is a new horizon in drug delivery system to 
enhance dissolution rate and oral bioavailability (Seckiguchi et al., 1964). 
This section highlights various approaches in solid dispersion technology. A 
schematic of the section is shown in figure 2.5.  
 
 
 
 
Figure 2.5 A schematic presentation of solid dispersions (Nijlen et al., 2007) 
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In 1961, Seckiguchi and Obi demonstrated a practical technique to overcome 
the bioavailability issue of a poorly water soluble drug which was termed a 
'solid dispersion' (Seckiguchi et al., 1964). Solid dispersion technology deals 
with groups of solids containing at least two components, normally a 
hydrophobic drug and a hydrophilic matrix. This matrix can be either in a 
crystalline or an amorphous form. Chiou and Riegelman defined solid 
dispersion as a “dispersion of one or more active moieties into an inert 
carrier at solid state prepared by a fusion, solvent or melting-solvent method” 
(Chiou et al., 1969). Traditionally, water soluble or water miscible polymers 
like polyethylene glycol, polyvinylpyrrolidone or low molecular weight 
compounds like urea, mannitol or citric acid were used as carriers. Typical 
polymer matrices are listed in table 2.1. 
Table 2.1 Polymers used in solid dispersions 
Chemical 
name 
Trade name Glass transition 
temperature (°C) 
Melting point 
(°C) 
Hydroxypropyl 
cellulose 
Klucel® 130 - 
Ethyl cellulose Ethocel® 133 240 
Polyethylene 
oxide 
Polyox®WSR -50 65-80 
Polyethylene 
glycol 
Carbowax® -20 37-63 
PVP Kollidon® 168 - 
Hydroxypropyl 
methyl cellulose 
Methocel® 175 - 
Cellulose - 165 192 
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Compared to conventional dosage forms, the advantages of solid dispersion 
are schematically presented in figure 2.6. 
Poorly water soluble drug 
 
                   Conventional forms                                       Solid dispersion 
 
                         Disintegration                                           Disintegration 
          Large solid particles                      Colloidal particles/ Fine oil globules 
                   (Usually 5-100 micron)                             (Usually < 1 micron) 
  Lower dissolution rate               Absorption into            Higher dissolution                      
                                                      Body system                    rate                
                                    
Figure 2.6 A schematic presentation of bioavailability enhancement of a 
poorly soluble drug (Singh et al., 2011) 
For conventional tablets and capsules, the primary particle size formed by 
disintegration is the rate limiting step for dissolution. In this case the average 
particle size is 5 µm even though a higher particle size is preferable for 
handling and manufacturing while solid dispersions dissolve immediately to 
saturate the GI fluid. Initially the main objective of solid dispersions was 
purely to increase the solubility of poorly water soluble drugs, but recently 
acetate 
phthalate 
Polyethylene - -125 140 
Dosage form
GI tract 
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this concept has been applied to the formation of sustained release drugs 
and to change solid state properties (James et al., 1997).  
Due to their potential to enhance the bioavailability of poorly water soluble 
drugs, solid dispersions have become one of the most active areas of 
research in the pharmaceutical industry.  
2.4.1. Classification of solid dispersion 
Based on molecular arrangements, solid dispersions can be broadly 
classified into the following types; simple eutectic mixtures, amorphous 
precipitations in crystalline matrices, solid solutions, glass solutions, complex 
formations of drug and matrices and amorphous precipitations, as shown in 
table 2.2.   
Table 2.2 Types of solid dispersion (Adapted from Singh et al., 2011) 
Type Matrix 
* 
Drug 
** 
Remark No. phases 
1. Eutectic C C The first type of 
prepared solid 
dispersion  
2 
2. Amorphous 
precipitation 
in crystalline 
matrix 
C A Rarely 
encountered 
2 
3 Solid solution     
Continuous solid 
solution 
C M Miscible at all 
compositions, 
never prepared  
1 
Discontinuous solid 
solution 
C M Partially miscible, 
2 phases even 
though drug is 
molecularly 
dispersed 
2 
Substitutional solution C M Molecular 
diameter of drug 
differs than 15% 
1 or 2 
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from the matrix 
diameter. In that 
case the drug and 
matrix are 
substitutional. 
Can be 
continuous or 
discontinuous. 
When 
discontinuous 2 
phases even 
though drug is 
molecularly 
dispersed.  
Interstitial solid 
solutions 
C M Drug molecular 
diameter less 
than 59% of 
matrix diameter. 
Usually limited 
miscibility, 
discontinuous. 
2 
4 Glass 
suspension 
A C Particle size of 
dispersed phase 
dependent on 
cooling rate. 
Obtained after 
crystallisation of 
drug in amorphous 
matrix. 
2 
5 Glass 
suspension 
A A Particle size of 
dispersed phase 
dependent on 
cooling rate. 
Obtained after 
crystallisation of 
drug in amorphous 
matrix. 
2 
6 Glass 
solution 
A M Requires miscibility 
or solid solubility, 
complex formation 
or upon fast 
cooling, 
evaporation during 
preparation. 
1 
*A: matrix in amorphous state, C: matrix in crystalline state 
**A: drug dispersed as amorphous cluster in the matrix, C: drug dispersed as 
crystalline particles in the matrix, M: drug molecularly dispersed throughout the 
matrix 
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2.4.1.1. Simple eutectic mixture 
A simple eutectic mixture involves two compounds which are completely 
miscible in the liquid state with limited distribution in the solid state. Generally 
differential scanning calorimetry of two compounds shows two endothermic 
peaks but in the case of a eutectic mixture, produces a single endothermic 
peak that lowers the melting point in comparison with the individual 
compound. This simple eutectic mixture can be prepared by various methods 
such as solvent, physical (grinding or mixing), solvent fusion and fusion 
methods.  
If a mixture consists of a slightly soluble drug and a highly soluble carrier in 
an aqueous media, the carrier will dissolve quickly resulting in the release of 
very fine drug particles (Tiwari et al., 2009).   
2.4.1.2. Solid solution 
A solid solution contains dissolved solid solute in a solvent. Two components 
crystallise together in one homogenous phase to form a mixed crystal 
(Dokoumetzidis et al., 2006). In solid solutions, the particle size is reduced to 
a molecular level to achieve higher dissolution than from a simple eutectic 
mixture. In accordance with Mohammed, in a binary system in which the 
formation of a solid solution is specious, the phase diagram is defined by the 
disappearance of a thaw point at a temperature higher than the eutectic point 
(Mohammed et al., 2001). Depending upon their miscibility, solid solutions 
are classified into continuous and discontinuous solid solutions and are 
based upon the solvate distribution in the solvent. Solid solutions are divided 
into amorphous substitutional and interstitial.   
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2.4.1.3. Continuous solid solution 
In continuous solutions, all components are miscible in all proportions. To 
date, no continuous solid dispersion has been reported in the pharmaceutical 
industry. Theoretically it represents that the bonding strength between two 
constituents is stronger than the bonding capacity of the individual 
components.  
2.4.1.4. Discontinuous solid solutions 
Here, the solubility of the two components is restricted in each other. In a 
particular composition and temperature region, one component is completely 
soluble in the other component. Below a certain temperature, the mutual 
solubility of the two constituents begins to decrease. As per practical 
consideration, Goldberg et al. suggested that the term 'solid solution' should 
be applicable when the mutual solubility exceeds 5% (Goldberg et al., 1965).     
2.4.1.5. Glass solution or suspension 
This concept was applied for the first time by Chiou and Riegelman for 
enhancing dissolution. It is a homogeneous system in which the solute 
dissolves in a glassy carrier (Chiou and Riegelman, 1969). The term ‘glassy’ 
describes materials which are transparent and brittle below the glass 
transition temperature (Fernandez et al., 1992). It is obtained by a rapid 
quench of the melt.  On heating, glass softens gradually and continuously 
without a sharp melting endotherm.  
2.4.1.6. Amorphous precipitation 
An amorphous precipitate forms when a drug precipitates as an amorphous 
form in an inert matrix. It is similar to a simple eutectic mixture. In an 
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amorphous precipitation the higher energy state of the drug leads to 
improved dissolution compared to the crystalline form of the drug. 
2.4.2. Advantages of solid dispersion 
A solid dispersion is useful to enhance the solubility and bioavailability of a 
poorly soluble drug. It leads to an increase in the degree and rate of 
absorption of a drug. Various parameters such as molecular weight, particle 
porosity, wettability and composition can be controlled, resulting in 
enhancement of the bioavailability of poorly water soluble drugs. The bitter 
taste of some drugs can be masked using this approach (Singh et al., 2011). 
2.4.3. Marketed solid dispersion products 
The commercial application of solid dispersions has so far been relatively 
limited, to date only a few formulations have been marketed which are 
displayed in table 2.3.  
Table 2.3 Marketed solid dispersion products 
Drug Trade Name Formulation Composition  
Ritonavir 
/Lipnovir 
Kaletra® Copovidone, sorbitan monolaurate, colloidal 
silicon dioxide and sodium stearyl fumarate 
Ritonavir Norvir® Copovidone, anhydrous dibasic calcium 
phosphate,  sorbitan monolaurate, colloidal 
silicon dioxide and sodium stearyl fumarate 
Itraconazole  Sporanox® Sugar spheres, hydropropyl methyl cellulose, 
gelatine, polyethylene glycol 
Etravirine Intelence® Hypromellose, silicified microcrystalline 
cellulose, croscarmellose sodium, lactose 
monohydrate 
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Tacrolimus Prograf® Lactose, hydropropyl methyl cellulose, 
croscarmellose sodium 
Rosuvastatin Crestor® Hypromellose, crospovidone, lactose, 
microcrystalline cellulose 
Griseofulvin Gris-PEG® Colloidal silicon dioxide, lactose, magnesium 
stearate, methylcellulose, methylparaben, 
polyethylene glycol 8000, povidone 
Nabilone Cesamet® Povidone and corn starch  
Ibuprofen  Solufen® Gelucire 44/14 
Vemurafenib Zelboraf® Hypromellose acetate succinate, 
croscarmellose sodium, colloidal silicon 
dioxide, magnesium stearate and 
hydroxypropyl cellulose 
Telaprevir Incivek® Hypromellose acetate succinate, 
croscarmellose sodium, colloidal silicon 
dioxide, dibasic calcium phosphate 
(anhydrous), microcrystalline cellulose, 
polyethylene glycol, polyvinyl alcohol, 
sodium lauryl sulfate and sodium stearyl 
fumarate  
2.4.4. Current trends in solid dispersion technology 
Innovative manufacturing processes to prepare solid dispersions have been 
developed to overcome drawbacks of traditional techniques. Solid 
dispersions can be categorised based on the implementation and recent 
development (Vasconcelos et al., 2007): 
2.4.4.1. First generation solid dispersions 
In 1961, Sekiguchi and Obi developed a eutectic mixture to enhance the rate 
of drug release which consequently increased the bioavailability of poorly 
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water soluble drugs (Sekiguchi and Obi, 1964). Later, Levy and Kaning 
prepared solid dispersions using mannitol as a carrier through molecular 
dispersions as an alternative to eutectic mixtures (Levy and Kaning, 1963). 
Crystalline solid dispersions were formed which are thermodynamically 
stable but did not release drug as the fast as amorphous form. 
2.4.4.2. Second generation solid dispersions 
In the late sixties, it was noted that solid dispersions with crystalline drugs 
were not effective as they were thermodynamically more stable. Hence, a 
second generation of solid dispersions was developed containing amorphous 
matrices (Singh et al., 2011).  
2.4.4.3. Third generation solid dispersions 
Recently, it has been illustrated that the rate of dissolution can be improved if 
the carrier has self emulsifying properties or surface activity, therefore the 
third generation of solid dispersions evolved. These involve using a 
surfactant as a carrier which enhances the bioavailability of the poorly 
soluble API; reducing recrystallisation and increasing the stability of the 
formulation (Singh et al., 2011).    
Table 2.4 Carriers used in different generations 
Generations Carriers 
First Sugar, organic acids, urea 
Second Starch derivatives such as cyclodextrin, cellulose, 
hydroxypropylcellulose, hydroxypropylmethylcellulose 
and completely synthetic polymers like polyethylene 
glycols, povidone, polymethacrylates 
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Third Tween 80, poloxamer 408, Gelucire 44/14 
2.4.5. Preparation of solid dispersions 
A number of methods have been developed to prepare solid dispersions 
(figure 2.7), details of which are provided below:  
 
Figure 2.7 Methods for preparation of solid dispersion 
2.4.5.1. Fusion method 
Sekiguchi and Obi introduced a fusion method to prepare solid dispersion 
where two components are mixed in the molten state achieved by heating 
(Sekiguchi and Obi, 1964).  The first solid dispersion of sulfathiazole and 
urea were prepared using this technique. At high temperature, several drugs 
or carriers may frequently evaporate and can decompose. To avoid this 
problem, physical mixtures should be heated in a sealed container or in the 
presence of an inert gas such as nitrogen. Hence, a high processing 
temperature is a downside of this technique (Drooge et al., 2006).  
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2.4.5.2. Solvent method 
An elementary technique which consists of two steps; the first step is the 
preparation of a solution containing a drug and carrier and the second stage 
includes the removal of the solvent to form a solid dispersion. This method 
requires the use of elevated temperature and a vacuum to remove the 
solvent, followed by drying the precipitate under a vacuum (Hem et al., 
1967). Various limitations are associated with this method; the main 
disadvantage is the use of organic solvents. It is difficult to choose and 
remove all of the solvent from the precipitate.  As a result, solvent traces can 
cause adverse effects and affect the stability of the components. Also the 
high preparation cost, selection of common organic solvents and difficulties 
in reproducing crystal forms are drawbacks linked with the solvent method.  
2.4.5.3. Melt solvent method or melt evaporation 
In this method a minimum amount of suitable organic solvent is used to 
dissolve the drug and then this solution is directly incorporated into a molten 
polymer such as polyethylene glycol followed by evaporation to obtain a 
solvent free and clear dispersion. The solid dispersion is then dried further to 
achieve a constant weight. Several disadvantages are connected with this 
method; it is not applicable to heat sensitive materials, and the solvent used 
may affect the polymorphic form of the drug (Fernandez et al., 1992).  
2.4.5.4. Super critical fluid (SCF) technology  
During the late 1980’s, SCF technology was first introduced into particle 
engineering. This technology encompasses the use of supercritical CO2 
under a specific temperature and pressure followed by rapid 
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depressurisation. For engineering of APIs  various SCF  techniques are 
available such as Rapid Expansion of a Supercritical Solution (RESS), Rapid 
Expansion of a Supercritical Solution into a Liquid Solvent (RESOLV), 
Gaseous Anti Solvent (GAS), Particles by Compressed Antisolvent (PCA), 
Supercritical Antisolvent (SAS), Aerosol Solvent Extraction System (ASES) 
and Solution Enhanced Dispersion by Supercritical Fluids (SEDS). These 
techniques deliver advantages such as the generation of high purity 
products, good control over crystal polymorphism, single step process green 
chemistry principles and high yields (Gentile et al.,  2007).  However, the use 
of supercritical CO2 solves problems associated with non-polar materials, but 
the co-solvent solubility effect of polar materials can be increased so it is a 
selective method. It may be disadvantageous to use supercritical solvents 
rather than organic solvents because of their lower effectiveness. 
Additionally, the scale up of this process is practically difficult.  
2.4.5.5. Spray drying 
This is a widely used technique to prepare solid dispersions. In this method, 
the drug and carrier are dissolved and then the solvent is removed by 
spraying it into a stream of heated air. It is cost effective and a simple 
technique.   
2.4.5.6. Hot melt extrusion (HME) 
HME has been used in the pharmaceutical industry mainly to prepare solid 
dispersions for improving the solubility of poorly water soluble drugs. 
Extrusion is a process whereby a mixture of drug and polymer is processed 
using a twin screw extruder. This technology is suitable for high doses as 
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well as for potent compounds. Solid dispersions prepared by HME can allow 
controlled release and provide improvements in dissolution behaviour. 
Furthermore, HME offers many advantages over traditional pharmaceutical 
operations; such as enhancing the bioavailability of poor water soluble drugs,  
solvent free processing, cost saving by reducing production time, capability 
of producing sustained, targeted and modified drug release, better content 
uniformity with different size ranges and uniform molecular dispersion. It is 
applicable to wide range of dosage forms and products have good stability. 
Additionally HME can be used for formulating clinically advantageous dosage 
forms for combating drug abuse and acting as a dose dumping deterrent. 
There are several pharmaceutical companies applying HME as a drug 
delivery technique including Soliqs, Germany and PharmaForm, USA. The 
use of HME is building rapidly and the technique is gaining significant 
attention within the pharmaceutical industry. However, High temperature 
processing is a major concern due to the thermal sensitivity of many drugs. 
A crystal engineering approach can be potentially used for a wide range of 
crystalline APIs. It has been reported that crystal engineering approaches 
served as a potential alternative for traditional solubility enhancement 
techniques. In fact, crystalline forms are recommended as they tend to be 
more reproducible, stable and amenable to purification than amorphous 
solids (Shan et al., 2008). However, polymorphs provide an opportunity to 
improve solid state properties without interrupting the molecules involved 
(Beyer et al., 2001 and Terada et al., 2000).   
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2.5. Polymorphs  
Engineering crystal properties by a choice of adequate molecular building 
blocks has to deal with the fact that a given API can be isolated in many solid 
forms such as single entity crystals, solvates, salts, co-crystals and their 
polymorphs each with its own characteristics and properties. Figure 2.8 
indicates schematic of the section.  
 
 
Figure 2.8 Solid forms of API 
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Polymorphism is the tendency of a molecule to adopt more than one 
crystalline phase. The significance of this phenomenon has been well 
studied in the past decade and it has gained fundamental, practical and legal 
interest from a range of industries including agricultural, pharmaceutical, 
food, explosives, pigments and dyestuffs (Day et al., 2005). Polymorphs and 
allotropes are closely related; polymorphism is the structural diversity of 
compounds whereas allotropy is used in general to refer to elements. For 
example, the gross property difference between diamond and graphite is well 
known (shown in figure 2.9) and this is a good example of how structure can 
affect properties. The carbon atom is the same in both the crystals however 
the arrangement of atoms is different in the different crystal structures which 
subsequently leads to the change in properties such as hardness and 
conductivity. In polymorphs, molecules exist in different patterns such as 
packaging, conformation and supramolecular synthons in the crystal lattice 
(Aceves-Hernandez et al., 2009).  
 
Figure 2.9 Allotropes of carbon; graphite and diamond (Adapted from 
Wikipedia http://en.wikipedia.org/wiki/Allotropy) 
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During crystallisation various forms may emerge depending on process 
parameters such as solvent type, temperature, additives and method of 
preparation. The polymorphs can be customised by solvent dependent 
processes, thermal or mechanical stress. Polymorph screening may be used, 
which combines the creative use of process variables with high throughput. 
In addition, advanced computational approaches to crystal structure 
prediction add a new tool to the anticipation and understanding of 
polymorphism. Therefore, it is a critical step to accurately assess polymorph 
properties and indentify the correct form of the API in the early stage of a 
drug's development. The famous assertion by the late Walter McCrone in 
1965, "the number of forms of a molecule is proportional to the time, money 
and experiments invested on that compound" has gained credence in recent 
years; as displayed by a significant increase in publications (McCrone, 
1965). Figure 2.10 shows flow chart for polymorphs.  
 
Figure 2.10 Flow chart or decision tree for polymorphs (Adapted from ICH 
guideline for polymorphism) 
2.5.1. Industrial significance 
Polymorphs may undergo interconversion as a result of external influences 
such as processing, crystallisation or storage conditions (Spruijtenburg et al., 
2000). The appearance of a novel crystal form at the early stages of 
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development may be useful, and is therefore classed as 'enabling'. At a later 
stage, the occurrence of a new form, especially a stable one which is not 
bioequivalent, may have catastrophic consequences on product performance 
and regulatory acquiescence. This issue is highlighted by 'disappearing 
polymorphs' i.e. the sudden appearance of a new crystal form (Davey et al., 
1997 and Bernstein, 2002).  In unfortunate cases, important forms may not 
be discovered during initial screening. A high profile case was Ritonavir 
(Norvir) semi-solid capsules (Chemburkar et al., 2000). When Ritonavir was 
developed only form I was known. Two years after market introduction in 
1996, it started to precipitate in the capsule and in some capsules failed to 
pass dissolution tests due to formation of the thermodynamically stable form 
II. Ritonavir forms I and II have a high solubility difference and the solubility 
differences in polymorphs can alter the rate of dissolution and bioavailability. 
As a result the original Ritonavir product had to be taken off from the market 
and a novel formulation of soft-gel capsules had to be created with extensive 
effort and investment. This polymorphic transformation during storage 
resulted in great market interruption of the product. The new Ritonavir 
formulation has made over $ 1 billion sales in five years and in 2003 the 
price of Ritonavir was increased by 400%. 
Polymorphism plays a pivotal role from the patent perspective in the 
pharmaceutical industry. This issue is highlighted by the Zantac patent case; 
GlaxoSmithKline's blockbuster histamine H2 receptor antagonist: ranitidine 
hydrochloride. This involved a legal battle between major generic companies 
concerning the solid-state generation of Form I of ranitidine hydrochloride 
without concomitant crystallization of Form II (Davey et al., 2003).  
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The generation of undesired polymorphs may occur through solvent 
mediated transformation during the crystallisation process (Tian et al., 2008; 
Sanphui et al., 2011 and Maruyama et al., 2001). In contrast, an 
understanding of these processes can lead to the desired crystal form being 
achieved. For example, L-glutamic acid, a naturally occurring amino acid 
essential for building protein blocks, adopts two crystal structures; the 
metastable α form and the stable β form (Ferrari et al., 2004). L-glutamic acid 
is used as a food additive and flavour enhancer in the form of salt known as 
monosodium glutamate in the food industry. It is crucial to isolate the α form 
rather than form β; the major challenge being to prevent its transformation. 
Polymorphic transformation of L-glutamic acid from α and β form is shown in 
figure 2.11. The stable β polymorph causes a situation whereby the 
crystallising slurry coagulates into a gel and cannot be processed further 
(Sugita et al., 1988). Garti et al. demonstrated that the addition of surface 
active agents lead to the favoured crystallisation of the α form (Garti et al., 
1997). Trimesic acid and transglutonic acid act as a conformational mimic of 
the α form which selectively inhibit nucleation of the β form and stabilise the 
α form.    
 
Figure 2.11 Polymorphic transformation of L- glutamic acid from α and β form 
Obtaining the right polymorph is important in the pharmaceutical industry; for 
example the broad spectrum anthelminthic drug mebendazole crystallizes in 
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three forms namely A, B and C (Brits et al., 2010). The commercially 
available form A is the most stable form whereas forms B and C are 
metastable forms. The solubility order for mebendazole polymorphs are B > 
C > A. Therefore form C is pharmaceutically preferred as its solubility is 
enough to ensure optimal bioavailability without showing the toxicity 
associated with form B. Many researchers pointed out that form A has no 
pharmacological activity either alone or when present in more than 30% in a 
polymorphic mixture. However, form C has a tendency to transform to the 
inactive form A; so it is desirable to stabilize form C by adding a surfactant, 
polymer or co-former (Kumar et al., 2008).       
The crystal tendency can have an impact on processing parameters such as 
bulk density, flowability and filterability. For example, theophylline exists in 
four polymorphic forms.  It has been reported by Suihko et al. that all four 
forms of theophylline have different processing characteristics (Suihko et al., 
2001). Another example is paracetamol; many pharmaceutical companies 
are interested in paracetamol polymorphs. Manufacturing analgesic 
paracetamol tablets requires a compaction process. Commercially available 
form I exhibits poor compressibility, so a time consuming and expensive wet 
granulation step is required.  Alternatively, Form II is more suitable for direct 
compression (Martino et al., 1997). 
These examples highlight the practical importance and consequences of 
polymorphism. It is therefore very important to identify different polymorphs 
of a substance, and to have control over the formation of different 
polymorphs at all stages of production to ensure product quality. 
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2.5.2. Thermodynamic and thermokinetic relationships  
The crystallisation of polymorphs involves a number of steps such as 
nucleation, crystal growth and transformation from the metastable to the 
stable form. In order to achieve selective crystallisation, a mechanical 
understanding of each stage and process dependant factors need to be 
clear. Wilhelm Ostwald stated that a system moves from a high energy state 
to an equilibrium without significant change in the free energy (Ostwald et al., 
1897). Therefore, the crystal that crystallises out first has the lowest energy 
barrier i.e. high energy level (kinetically metastable form). This form would 
then transform to the relatively low energy level until the lowest energy state 
(thermodynamically stable form) is reached. This is known as 'Ostwald's rule 
of stages'. Hence, a polymorphic system would shift through each possible 
crystal form until it reaches the most stable phase.   
From a thermodynamic point of view, under constant pressure polymorphic 
systems are categorised as monotropic and enantiotropic systems (Burger et 
al., 1979). The process involving the transition of one form into another form 
is called a phase transition and this may occur at constant pressure by 
changing the temperature according to the phase rule. In enantiotropic 
systems, the phase transition is reversible and the transition energy is 
endothermic on heating. In contrast, if the phase transition is irreversible the 
two polymorphs are monotropically related. In this case only one form is 
stable compared to the others regardless of temperature. The heat of fusion 
rule states that in a monotropic system the higher melting point polymorph 
will have a higher heat of fusion. If a high melting point polymorph has a 
lower heat of fusion then the two forms are enantiotropically related.  
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A number of analytical techniques are used to understand the 
thermodynamic relationship between polymorphs such as Hot Stage 
Microscopy (HSM) and Differential Scanning Calorimetry (DSC). DSC can be 
used to provide quantitative information about the relative stability of 
polymorphs, the energy involved in the phase transition and the enatiotroopic 
or monotropic behaviour of these transitions. However, HSM can serve as a 
qualitative tool to visualise morphological changes during phase transition 
under optical microscopy.    
2.5.3. Regulatory aspects 
Regulatory concerns can be classed as purity, stability, strength, 
bioequivalence, quality, toxicity, safety and efficacy of the drug molecule and 
the drug formulation (Vippagunta et al., 2001). As polymorphs differ in their 
dissolution profile and stability, there are regulatory concerns over the 
characterisation of reproducible forms to ensure the original properties. 
Preferably, one should select a commercially accepted form. However if 
current marketed drugs are under patent, one can use a newly invented 
form. Regarding regulatory guidelines, the discovery of a new polymorph 
offers an opportunity to generic manufacturers to introduce innovative 
products. The FDA and European regulatory authorities require the solid 
state properties of molecules to be analysed from safety and efficacy 
perspectives with respect to the drug product (Vippagunta et al., 2001). 
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2.6. Hot melt extrusion 
 
Hot melt extrusion (HME) - melting a physical mixture and forcing it through 
an orifice under a controlled set of conditions to prepare a contemporary 
material is a promising pharmaceutical technology for the preparation of 
different dosage forms and drug delivery systems. Extruders for 
pharmaceutical use have been specially designed and adapted for mixing 
drugs with carriers in various dosage forms. This section is primarily focused 
on equipment design, principles, applications and limitations of HME. A 
schematic presentation of HME process and solid dispersions are displayed 
in figure 2. 
                  
 
 
 
Figure 2.12 A schematic presentation of HME process and solid dispersions 
(Adapted from Ali et al., 2012) 
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Extrusion dates from the 1930s as a process used for producing polymeric 
coatings for wire insulation. In 1940, extrusion was used for the first time in 
the plastics industry for bulk manufacturing. Currently, extrusion is one of the 
most widely used processing techniques in the plastics, rubber and food 
industries. Extrusion is the process of converting raw material into a uniform 
shaped product by pushing it through a die under controlled conditions. 
Recently, this technique has been successfully applied to the pharmaceutical 
industry by scaling down. Furthermore, it is a solvent free technique and the 
availability of a broad variety of pharmaceutical excipients and polymers is 
advantageous for this hot melt extrusion technique. HME is considered to be 
an efficient technique with particular benefits over solvent based processes 
such as co-precipitation (Breitenbach et al., 2002). HME is a continuous 
technique that allows for the preparation of desired formulations in a single 
step with pharmaceutical as well as economic advantages. The number of 
patents issued related to HME in the pharmaceutical industry has been 
increasing continuously (figure 2.13). This technique has been widely used in 
the pharmaceutical industry for preparing solid dispersions; it is a process 
where drug and excipients are melted and then forced through a die and, 
depending upon the purpose, shaped into granules, pellets, tablets, film or 
milled into powder (Rauwendaal et al., 1986). 
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Figure 2.13 Use of hot melt extrusion for pharmaceutical applications by 
country (adapted from Zang et al. 2007) 
Published literature concerning HME has shown an increased interest of this 
technique within the pharmaceutical industry. It can provide novel and 
innovative drug delivery approaches such as solid dispersions, effervescent 
granules, transdermal films, complex formations, co-crystal formations and 
sustained release formulations.  
2.6.1. Equipment 
 
Figure 2.14 Thermo Pharmalab hot melt extruder 
Hot melt extruders such as the example (shown in figure 2.14) come with 
downstream processing auxiliary equipment and monitoring tools for 
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evaluating performance and product quality such as temperature gauges, 
screw-speed controller, extrusion torque monitor and pressure gauges 
(Kruder et al., 1985). Typically, the extruder is composed of a feeder, a 
hopper, a barrel, single or twin screws, a die and a screw drive unit. The 
auxiliary unit is composed of heating and cooling devices for the barrel, 
conveyor belt for cooling down the product and a solvent injection pump. 
Inside a stationary cylindrical barrel, the extruder consists of one or two 
rotating screws; this cylindrical barrel is manufactured from a single piece or 
from separate sections and clamped together. At the end of the barrel an end 
plate or die is connected which determines the shape of the extrudate.  
2.6.2. Types of hot melt extruder 
Based on operating principles hot melt extruders may be broadly classified 
into ram and screw extruders. The classification of extruder is shown in 
figure 2.15.   
                                  
                         Figure 2.15 Types of extruder 
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2.6.2.1. Ram extruder 
High pressure is the operational principle of ram extrusion. This high 
pressure is generated through the positive displacement of a ram. During 
ram extrusion, materials are introduced into a heated cylinder, then the 
softened material is forced through a die under pressure and converted into 
the desired shape (Perdikoulias et al., 2003). Ram extrusion has a limited 
heating ability which can cause variances in temperature distribution.  In 
comparison with screw extruders, ram extruders produce products with 
limited homogeneity and have high residence times. 
2.6.2.2. Screw extruder 
Screw extruders are further categorised into single screw and twin screw. 
The major differences are the methods of conveying or transporting the 
material (Rauwendaal et al., 1984). A schematic presentation of single and 
twin screw extruders is displayed in figure 2.16.   
 
Figure 2.16 Cross-section of single and twin screw extruder barrel (Adapted 
from Particle sciences drug delivery services, Technical Brief 2011, vol. 3) 
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Single screw extruder 
Single screw extruders (displayed in figure 2.17) are the most widely used 
types of extruder. A single screw in a heated barrel rotates and is 
responsible for a number of processes such as material conveying or 
transporting, melting, devolatilising and pumping.  
 
Figure 2.17 Single screw extruder (Adapted from plastics.com) 
                                               
The operating principle of single screw extrusion is based on frictional forces 
and viscous forces in the conveying zone. Hence, extrusion is significantly 
dependent on the frictional and viscous properties of materials being 
processed. The mass flow is set by the feed system and is dependent on the 
screw rotation speed. Generally the screw is driven from the hopper end, and 
if the screw diameter is less than 18 mm, it becomes weak and some 
variation may occur. To overcome these associated problems, a vertical 
screw may be used driven from the discharge end (Luker et al., 2003). Single 
screw extrusion offers a high efficiency to investment ratio. Though it has a 
simple mechanism, it is simple to operate, has a relatively low cost and has a 
limited mixing capability. A comparison of mixing capacities of single and 
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twin screw extruders was made by Ferns by adding coloured dye to the 
material being processing. Extrudates obtained from a single screw extruder 
had bands with several shades but extrudates from the twin screw extruder 
had uniform colour distribution (Ferns, 1974). 
Twin screw extruder 
As the name suggests, twin screw extruders incorporate two screws which 
are located side by side inside the barrel. During the late 1930’s the first twin 
screw extruder was developed in Italy. It is a more efficient process than 
single screw extrusion because in the twin screw extruder mixing occurs at a 
macroscopic as well as microscopic level. At The macroscopic level, the 
material is exchanged between two screws and at the microscopic level, 
mixing occurs at high shear regions of the screw element interaction.  
Different twin screw elements are displayed in figure 2.18.      
 
Figure 2.18 Twin screw elements 
The twin screw extruder is characterised by the following features: 
 Short residence time: In a typical extrusion process, residence time 
is up to 2 min.   
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 Self-wiping: Extruder screws are self-wiping and ensure the emptying 
of the barrel and minimum wastage during shutdown.  
 Minimum inventory: This is significant when processing hazardous 
materials.  
 Versatility: Processing parameters can be modified continuously and 
it is relatively easy to change the degree of mixing. Modular screw 
elements allow different screw configurations to be used to achieve 
high or low shear for the respective application (Whelan et al., 1996). 
These screws are interchangeable and can be swapped to suit each 
application. Dies can also be exchangeable therefore it allows a 
variety of formulation processes in a single piece of equipment. It is 
applicable for a wide range of polymers with low viscosity and fine 
powders can be processed directly through the system.   
2.6.3. Extruder design  
Commercially available twin screw extruders have a modular design to aid 
screw alternation. The screw design has a major impact on the extrusion 
process and can be designed to achieve particular shear intensities and 
residence times. Whelan et al. studied various available screw designs 
(Whelan et al. 1996). In HME, screw dimensions are usually specified in 
terms of their length/diameter ratio (L/D). For example, a screw with length of 
1000 mm and diameter of 25 mm indicates a 40:1 L/D ratio. Typically, 
extruder screw dimensions vary from 25:1 to 40:1. For a single screw 
extruder, this should be 36:1 or less, for intermeshing twin screw extruders it 
can be 60:1 or shorter and for non-intermeshing twin screw extruders the    
L: D ratio may be 100:1 or higher due to the intermesh clearance restriction 
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(Steiner et al. 2003). Another common term is ‘screw diameter’ e.g. 20 mm 
screw diameter indicates the diameter of a single screw or the diameter of 
each screw in a twin screw extruder. The OD/ID (outer diameter / inner 
diameter) determines the available free volume.  There are two types of free 
volume gaps; flight gap and intermesh gap. The flight gap is the gap between 
the OD and the barrel while the intermesh gap is the gap between two 
screws in the case of a twin screw extruder. Channel or flight depth is an 
important extruder design factor because torque is directly proportional to the 
channel depth (Chokshi et al. 2004). In extruder design, it is necessary to 
find out the most favourable equilibrium between the free volume and the 
torque to achieve the maximum throughput.  
2.6.4. Process 
Theoretically the extrusion process (displayed in figure 2.19) is divided into 
four parts (Breitenbach et al., 2002). 
1. Feeding 
2. Conveying  
3. Flow through die 
4. Exit from die and down-stream processing  
 
 
Figure 2.19 Hot melt extrusion process (Adapted from Particle sciences drug 
delivery services, Technical Brief 2011, vol. 3) 
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Material is fed from a hopper to the feeding section which has a deeper 
channel depth. This configuration facilitates the feed material to drop easily 
into the screws for transporting along the barrel. At a steady screw speed, 
the helix angle and pitch control the throughput. The solid plug of material is 
conveyed to the transition zone for mixing, compressing, melting and 
plasticizing (Breitenbach et al., 2002). Once the material enters into the 
compression zone, the polymer begins to melt. The temperature of the 
compression section is usually set above the glass transition temperature of 
the polymer (McGinity et al., 2007). Compression is achieved by reducing the 
thread pitch without controlling a constant flight depth or by reducing flight 
depth with controlling a constant thread pitch (Johnson et al., 1982).  An 
increase in pressure occurs in both processes as the material shifts along 
the barrel. Molten material moves in a helical path due to the pressure flow, 
transverse flow, leakage and drag flow. The gap between the barrel width 
and the screw diameter is in the range of 0.1 to 0.2 mm (Martin et al., 2001).  
The material reaches the metering zone in a homogeneous plastic form 
which is ideal for extrusion through a die. The metering zone is responsible 
for lowering the pulsating flow of the material and for ensuring uniform 
release through the die plate (Breitenbach et al., 2002).  
The monitoring and understanding of several parameters is necessary for 
successful extrusion. Barrel temperature, screw speed and feed rate are 
controlling parameters while melt pressure and motor load are parameters 
which can be monitored to provide a valuable indication of the state of the 
process.  
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 Barrel temperature: The glass transition temperature, melting and 
degradation temperature of polymer and drug determines the barrel 
temperature.  
 Screw speed and feed rate:  Screw speed and feed rate have a 
great influence on the extrusion process. It is essential to manage the 
balance between strong and weak mass transfer. Constant screw 
speed and feed rate assures a constant amount of material in the 
extruder and therefore the shear intensity and residence time remains 
constant (Martin, 2001).  
 Die melt pressure: The screw speed, feed rate and melt viscosity 
determines the melt pressure. Screw speed and feed rate parameters 
are set based on the properties of the polymer and drug e.g. 
molecular weight, miscibility capacity (Breitenbach et al., 2002).  
2.6.5. Materials used in HME processing 
The materials used in the HME must meet the same guidelines for purity and 
safety as those used in conventional methods. HME has been widely used 
for the preparation of solid dosage forms such as tablets, granules, pellets, 
powder and transdermal patches. The materials employed for HME 
processing must display, to some extent, thermal stability with an accepted 
degree of physical and chemical stability. The thermal stability of each 
component and mixture should be enough to endure the preparation process 
(James, 2004).  
Extrudates are complex mixtures of APIs and functional excipients. 
Excipients can be broadly categorised into polymers, plasticisers, release 
modifying agents, bulking agents and other additives (Chokshi et al., 2004). 
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The excipients can convey a particular property to the extrudates as similar 
to those dosage forms prepared by traditional methods (Follonier et al., 
1995).  
2.6.5.1. Active Pharmaceutical Ingredients (APIs) 
The properties of APIs can often limit the available options of formulations 
and preparation methods, in preparing an acceptable dosage form. HME is a 
comparatively new technique to the pharmaceutical industry which offers 
several advantages. This is an anhydrous method, therefore it can prevent 
the degradation of the potential candidates because no hydrolysis can take 
place. Additionally, poorly compressible materials can be integrated into 
tablets prepared by cutting an extruded rod, reducing the problem usually 
seen in traditional methods. APIs should be stable in the extrusion process, 
this is very important to access the thermal, physical and chemical 
properties. Depending on the distinctive properties of the drug and other 
excipients, the drug may be present in undissolved particles or in a solid 
solution. The state of drug in the formulation stage may have an influence on 
the stability and processibility (James, 2004).  
2.6.5.2. Polymers   
In HME, the API is embedded in a carrier matrix containing one or more 
meltable compounds and other additives. The meltable compounds can be 
polymeric materials (Zhang et al., 1998) or low melting waxes (Miyagawa et 
al., 1996).  
The selection of polymers for the HME process primarily depends on 
polymer stablity, drug-polymer miscibility and the purpose of the desired 
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dosage form. A number of carrier systems have been used in the 
pharmaceutical industry for the extruded dosage forms.   
Such polymer systems comprise of polyvinylpyrrolidone (PVP) 
(Tantishaiyakul et al., 1999) and its co-polymers such poly(ethylene-co-vinyl 
acetate) (Follonier et al., 1995), polyvinylpyrrolidone-vinyl acetate (Zingone 
et al., 1992), a variety of polyethylene glycols grades, acrylates (Abd et al., 
1998) and cellulose ethers (Yano et al., 1997), different molecular weight  
polyethylene oxides (Zhang et al., 1998), poly methacrylate derivatives and 
poloxamers. Along with different classes of biodegradable polymers, the 
thermoplastic aliphatic poly (esters) such as poly (lactide) (PLA), poly 
(glycolide) (PGA) and copolymer of lactide and glycolide, poly (lactide-co-
glycolide) (PLGA) have been exploited in extrusion. Starch and starch 
derivatives have been applied along with low molecular weight excipients like 
sugars and sugar alcohols and waxes (Ndindayino et al., 2002). For HME 
use, the basic requirement is the thermo plastic properties of the polymer.  
2.6.5.3. Plasticisers 
Polymeric carriers may require the incorporation of the additional plasticiser 
into the system in order to improve the processability and the physical and 
the mechanical properties of the extrudates (James 2004). Plasticisers are 
added during manufacturing of the extruded dosage forms to facilitate the 
extrusion of the material and to amplify the flexibility of the extruded material. 
This approach may allow for the processing of heat sensitive drugs or 
polymers by reducing the processing temperature (Karen et al., 2006). The 
selection of a suitable plasticizer is based on the polymer-plasticiser 
compatibility and the stability of plasticiser. A varity of plasticisers are 
Chapter 2: Background 
 
NOVEL FORMULATIONS OF A POORLY SOLUBLE DRUG USING THE EXTRUSION PROCESS 
 Page 48 
 
available such as triacetin (Follonier et al., 1995), citrate esters (Aitken-Nicho 
et al., 1996), and low molecular weight polyethylene glycols (Follonier et al., 
1995). 
Plasticisers lower the glass transition temperature (Tg) of the polymer, thus 
improving the stability profile of the API and polymer. A drop in Tg depends 
on the category and the level of the plasticiser (James, 2004). Plasticizers 
reduce the shear forces required to extrude a polymer, by this means, one 
can improve the processing of the high molecular weight polymers (Zhang et 
al., 1998).  As an assessment, the themo-chemical stability and volatility of 
the plasticiser throughout processing and storage should be considered 
(Repka et al., 1999).  
2.6.5.4. Other additives  
The dissolution rate of an API from the extrudates can be increased or 
decreased by incorporating rate modifying agents. For a mixture that 
undergoes degradation by oxidation or free-radical degradation during 
processing and storage, the addition of antioxidants and light absorbers or 
acid acceptors is recommended (James, 2004). Generally antioxidants are 
divided as preventive antioxidants or chain breaking antioxidants. Preventive 
antioxidants avoid the generation of free radical chain reactions. Preventive 
agents such as ascorbic acid, can interfere with auto-oxidation in a 
preventative way since they preferentially undergo oxidation. These agents 
protect APIs and polymers from an oxygen molecule attack and can be 
known as oxygen scavengers. They are mainly efficient when employed in a 
closed system where oxygen cannot be replaced once it is consumed.   
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Chelating agents are another type of preventive antioxidant that reduce the 
free radical formation rate by forming a stable complex with metal ions which 
catalyse these types of reduction reactions e.g. edetate disodium (EDTA) 
and citric acid. Waxy materials such as glyceryl monostearate are used to 
function as a thermal lubricant during hot-melt processing (Crowley et al., 
2007). 
2.6.6. Applications of HME  
2.6.6.1. General applications 
Extrusion has wide range of applications in the plastics and rubber industry, 
it is used for the production of pipes, sheets, hoses, insulated wires and 
cables and polystyrene tiles. Common polymers such as acrylic, 
polyethylene, polypropylene, nylon, polyvinyl chloride, polystyrene and 
polycarbonate are used for plastic manufacturing. Profile extrusion describes 
a process where the die determines the shape of the extrudate e.g. a tube or 
more complex shape. The extruded profiles are further processed 
horizontally; their length controlled by cut off equipment. These profiles can 
be processed further, for example, by orientation in film or blow moulding 
(Schott, 1983). Since the 1930s, extrusion has also been utilized in the food 
industry for the production of pastas and cereals. This versatile process 
combines mixing with cooking (Senouci, 1985). 
2.6.6.2. Pharmaceutical applications 
The dissolution profile of an orally administered formulation is highly 
dependent on the solubility and permeability of the drug.  It has been 
estimated that approximately 40% of innovative molecular entities have poor 
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aqueous solubility and hence low bioavailability. This proportion is increasing 
because of the introduction of combinational chemistry and the significance 
of lipophilic receptors (Kerns, 2001). Formulation scientists are trying to 
concentrate on the solubility issues caused by assorted pharmaceutical 
interferences. Currently, researchers are attracted towards solid dispersions 
to improve the dissolution and bioavailability of poorly water soluble drugs. 
HME is a convenient technology to prepare solid dispersions. Implants, oral 
dosage forms, stents, topical films, bioadhesive ophthalmic inserts, 
effervescent tablets and implants have all been prepared using this 
technology (Repka et al., 2007).  
Over the last two decades the importance of ‘continuous processing’ has 
been recognised by the pharmaceutical industry. HME is an efficient 
technique for preparing drug delivery systems. Comparatively lower capital 
investment and labour costs are key advantages of HME apart from it being 
a solvent free technology (Gamlen, 1986).  
Research in this area is growing and published literature exposes many 
novel and innovative aspects. Pharmaceutical applications of this technology 
include sustained release systems, films for transdermal delivery, taste 
masking and crystal engineering (schematic is shown in figure 2.20). Some 
key developments in HME are discussed below. 
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Figure 2.20 Variety of applications of HME 
Sustained released systems 
In 1990, Mank et al. studied extrusion of various thermoplastic polymers to 
prepare sustained release pellets. In 1994, Follonier et al. produced 
sustained release pellets containing the freely water soluble drug diltiazem 
hydrochloride using HME. The influence of polymers, polymer to drug ratio 
and the size of pellets on drug release were examined (Follonier et al., 
1995). Examples of different polymers include ethyl cellulose, cellulose 
acetate butyrate, polyethyl acrylate/methyl methacrylate/trimethyl ammonio 
ethyl methacrylate chloride and polyethylene-co-vinyl acetate (EVAC). 
Triacetin and diethyl phthalate were employed as the plasticisers. The pellets 
showed a smooth surface, low porosity and slow drug release. 
Theophylline pellets for controlled release were prepared by hot melt 
extrusion method using Eudragit and poly ethylene glycol 8000 polymers. In-
vitro studies showed a controlled release pattern which was influenced by pH 
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dependent dissolution and polymer swelling (Shaikh et al., 1987 and Young 
et al., 2005).   
Miyagawa et al. produced controlled release diclofenac granules using twin 
screw extrusion and proved that good mechanical strength wax matrix 
granules could be achieved at a temperature below the melting point of wax 
(Miyagawa et al., 1996). Shimpi et al. discovered the application of Gelucire 
43/01, a hydrophobic lipid for designing a multi-unit floating drug delivery 
system of a highly water API such as diltiazem HCl using a melt granulation 
technique. Approximately 65% to 80% drug release was achieved over 6 
hours with an initial fast release from the surface (Shimpi et al., 2004).  
Mehuys et al. developed alternative techniques for preparing an enteric 
coating system, offering continuous and rapid processing using polyvinyl 
acetate phthalate and hydroxyl methyl cellulose as a means of HME 
(Mehuys et al. 2005). Similarly, gastro-resistant matrix tablets were 
successfully prepared using HME containing acrylate polymer 
Eudragit® L100-55. The presence of plasticiser triethyl acetate, an acidity 
modifier (citric acid) and hydrophilic polymers (Kollidon 30 and Carbopol 
971), significantly enhanced the drug release. Moreover drug release was 
dependent on the concentration of triethyl acetate and the pH of the media 
(Andrews et al., 2008).  
The thermal stability of Poly(ethylene Oxide) (PEO) in SR released tablets 
was studied and it was found that chemical stability of PEO was dependent 
on the storage conditions, processing parameters and the molecular weight 
of the polymer (Crowley et al., 2002). Oshlack et al. patented a melt 
extruded, orally administrable, opioid formulation containing a plurality of 
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multiparticulates (Oshlack et al., 2004). Fukuda et al. studied the influence of 
pH, selected buffer and the ionic strength on chlorpheniramine maleate 
release and the release mechanism from sustained release tablets 
containing chitosan and xanthan gum produced by HME. The extruded 
tablets showed pH and buffer independent sustained release (Fukuda et al., 
2006).   
Vervaet et al. manufactured sustained release ibuprofen and metoprolol 
tartrate using ethylcellulose as a carrier (Verhoeven et al., 2008). 
Vasanthavada et al. explored the application of HME for melt granulation to 
develop a high dose, modified release tablet formulation (Vasanthavada et 
al., 2011). Melt granulation technology using HME has emerged as a robust 
and significantly useful technique for generating modified release oral 
formulations with high dose.   
Films for transdermal delivery 
The application of HME for preparing elastic and thin acrylic films for 
transdermal delivery was investigated by Aitken-Nichol et al. This study 
involved a comparison between cast films using various methods and found 
that HME was a practically feasible technology for preparing acrylic resin 
films (Aitken-Nichol et al., 1996). Traditionally, cast films were produced 
using aqueous or organic solvents for transdermal and transmucosal delivery 
systems. Repka et al. reviewed several drawbacks of these solvent based 
methods such as time consuming, expensive and environmental damage 
(Repka et al., 1999). They prepared hot melt extruded bioadhesive films 
containing ketoconazole and Carbopol 974P NF for topical onychomycosis 
therapies (Repka et al., 2004). Muco-adhesive matrix films of clotrimazole 
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(10% w/w) were developed for local drug delivery for oral candidiasis. The 
formulation contained polymer carriers such as hydroxypropyl cellulose and 
poly(ethylene oxide), bio-adhesive  polycarbophil and excipients (Repka et 
al., 2003). The effect of tartaric acid on the bioadhesive, moisture sorption 
and mechanical properties of extruded hydroxypropyl cellulose and polymer 
additives were investigated (Mididoddi et al., 2006).  The added tartaric acid 
significantly influenced the bio-adhesive and mechanical properties of the 
film.  
Mididoddi et al. studied the physicochemical properties of melt extruded bio-
adhesive films for onychomycosis treatment and successfully determined the 
stability of the antifungal drug incorporated in these films. The thermal 
behaviour, surface morphology and crystalline properties were investigated 
by DSC, SME and PXRD respectively. The obtained data demonstrated that 
the melt cooled mixture of API and polymers reached an amorphous state 
(Mididoddi et al., 2006).  
Thin films containing the model drug clotrimazole and two different molecular 
weights of poly(ethylene) oxide (PEO) were prepared using HME and their 
solid state, bio-adhesive and mechanical properties were studied (Prodduturi 
et al., 2005).  PXRD patterns showed the recrystallisation of the drug after 
storage for 3 months at 25°C / 60% Relative Humidity (RH). The inadequate 
physical stability of the drug and PEO system may be due to the low glass 
transition of PEO and its tendency to fold upon cooling from the melt.  
Oral, muco-adhesive thin films of the cellulosic polymers such as 
hydroxypropyl cellulose (HPC) and hydroxypropyl methyl cellulose (HPMC) 
loading, with a topical anaesthetic lidocaine were produced using HME 
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(Rekpa et al., 2005). Two formulations were prepared, one containing only 
HPMC and the drug and the other containing the drug and HPC:HPMC 
(80:20). Both formulations showed sustained release and the mechanism 
was mainly diffusion of lidocaine through the carrier matrix. Incorporation of 
HPMC delayed the drug release and enhanced adhesive properties. These 
types of films would be advantageous for dental procedures and topical 
applications.  
Cilurzo et al. reported that oral, fast dissolving films of maltodextrins with 
piroxicam can be prepared using HME (Cilurzo et al., 2008).  
Solubility or bioavailability enhancement 
A solid dispersion can be prepared to enhance the solubility of poorly soluble 
APIs. Different techniques are used to produce solid dispersions such as 
melting method, solvent method, melting solvent method (melt evaporation), 
lyophilization techniques, melt agglomeration process, the use of surfactant, 
electrospinning and Super Critical Fluid. Karanth et al., stated the use of 
HME as an alternative feasible approach in the field of solid dispersion 
(Karanth et al., 2006). In 1969, cellulose acetate phthalate pellets were 
prepared using a rudimentary ram extruder and their dissolution rate with 
respect to pellet geometry was studied (Rippie et al., 1969). 
De Brabander et al. suggested the use of HME for manufacturing matrix mini 
tablets that minimised the risk of dose dumping, reduced inter and intra-
subject variability and offered highly dispersive formulations within the 
gastrointestinal tract (De Brabander et al., 2003). The capability of HME for 
wettability to improve the drug release pattern of engineered particles was 
demonstrated by Miller et al. (Miller et al., 2007). The dissolution and the 
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bioavailability of a poorly soluble BCS class II drug felodipine was 
significantly enhanced by preparing its solid dispersion with Kollidon® VA64. 
The amorphous state of the extrudates were confirmed by PXRD and (13) C 
CP/MAS nuclear magnetic resonance (NMR) analysis. The molecular level 
mixing prevented the drug from recrystallisation when stored even at 40°C / 
75% RH for almost 2 months (Song et al., 2013).    
Fukuda et al. investigated the influence of sulfobutyl ether beta-cyclodextrin 
(SBE(7)-beta-CD; Captisol on the dissolution rate of ketoprofen. Extrusion 
was performed at 100°C, near to the melting temperature of ketoprofen. The 
physicochemical properties and drug release were studied and compared 
with samples obtained from co-grinding, heat treatment, freeze drying and 
physical mixture. The extruded sample showed a significantly faster 
dissolution rate and was least affected by the moisture (Fukuda et al., 2008).  
Tang et al. demonstrated that HME is a useful technique to prepare solid 
dispersions of fenofibrate with Eudragit E100 and polyvinylpyrrolidone vinyl 
acetate copolymer S600 and is a remarkable tool for enhancing the solubility 
and bioavailability of finofibrate (He et al., 2010). Nano or micro dispersions 
of ritonavir were prepared by dispersion of ritonavir melt extrudates in an 
aqueous media. The dissolution rate was significantly improved in the melt 
extrudates in comparison with the crystalline API (Tho et al., 2010). Perissutti 
et al. used HME to enhance the dissolution rate of carbamazepine (Perissutti 
et al., 2002).   
In 2010, DiNunzio et al. reported the application of appropriate formulation 
techniques and novel manufacturing processes such as Kinetisol® 
dispersing for preparing solid dispersions without adding any solvent or 
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plasticiser. This technique can be used to improve the physicochemical 
properties, homogeneity and solid state stability of the solid dispersion. It is 
an innovative, high energy process which utilises a combination of shear and 
frictional energies to rapidly prepare hydrophilic and plasticiser-free solid 
dispersions. In this study, an example of itraconazole - Eudragit L 100 was 
demonstrated (DiNunzio et al., 2010).   Tho et al. discussed the preparation 
of a nano or micro dispersion of a protease inhibitor, an anti-HIV 
drug ritonavir melt extrudate in aqueous media (Tho et al., 2010). The 
system was formed by dissolving the extrudate in a hydrophilic carrier 
containing a surfactant and this was dispersed in an aqueous medium. The 
dissolution profile and drug release was improved in comparison with pure 
crystalline drug.   
HME has been widely used to increase the bioavailability of a poorly soluble 
drug by forming a molecular dispersion (Breitenbach et al., 2003). This 
application can be explained from the example of Kaletra®, a combination of 
lopinavir and ritonavir as mentioned by Rosenberg et al. in the US patent 
(Rosenberg et al., 2005 and Rosenberg et al. 2007). Before, the combination 
of lopinavir and ritonavir was marketed for oral delivery as soft gel capsules 
since both the APIs are insoluble in water. The dosage was three capsules 
twice a day with food to maximise the bioavailability of lopinavir and these 
capsules require refrigerated storage to prevent degradation. However, the 
tablet formulation prepared using HME reduced the number of dosage units 
taken per day and simplified the storage conditions.      
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The coating of hot melt extruded tablets with suitable polymers has been 
shown to extensively delay the onset of crystallisation during dissolution and 
storage (Bruce et al., 2010).  
Taste masking 
The taste masking of bitter drugs is one of the major challenges, particularly 
for the preparation of orally disintegrating tablets. HME has proved to be an 
efficient and effective technique to mask the bitter taste of APIs by preparing 
solid dispersions using taste masking drug carriers. Eudragit EPO has been 
used to mask the taste of ibuprofen and granules were prepared by HME. 
The taste masking principle is based on the ionic interactions of 
complimentary ionic groups. The anionic polymer interacts with the cationic 
drug or vice-versa to mask the taste. These types of interactions give rise to 
hydrogen bonding and subsequently mask the bitter taste of APIs. (Gryczke 
et al., 2011). Maniruzzaman et al. have achieved taste masking of 
paracetamol through intermolecular forces between the drug and polymer by 
processing oppositely charged components (Maniruzzaman et al., 2012).  
Crystal engineering  
Patent GB2009/050924 by Paradkar et al., discloses the use of extrusion for 
Solvent-Free Continuous Co-crystallisation (SFCC) technology. The patent 
claims that extrusion is an excellent technique for generating co-crystals 
whilst at the same time being easily amendable to a quality by design (QbD) 
approach, a new paradigm in the pharmaceutical industry.    
Dhumal et al. produced agglomerated cocrystals of ibuprofen- nicotinamide 
using the HME technique. This technology offers tight control over the 
process parameters with the flexibility for modifying the purity of the co-
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crystal. It also allows online monitoring by adapting process analytical 
techniques such as NIR and Raman spectroscopy (Dhumal et al., 2010).  
2.6.7. Marketed formulations using HME technology 
Various pharmaceutical companies across the globe are currently using 
HME as a drug delivery technique. Melt extrusion has also been confirmed to 
be a suitable method for the production of controlled release reservoir 
systems containing polyethylene vinylacetate (EVA) co-polymers. Implanon® 
and Nuvaring®, two controlled release systems have been developed based 
on this technology. Some of the formulations prepared by hot melt extrusion 
are shown in table 2.5. 
Table 2.5 Marketed formulations using HME 
Formulation with specification Company 
Kaletra (For HIV treatment) SOLIQS, Germany 
Verapamil (Isoptin SRE) SOLIQS, Germany 
Ibuprofen fast onset SOLIQS, Germany 
PharmaForm has developed an extrusion based technique: PharmaForm 
Abuse Deterrent Technology (PADT), to prevent and deter drug abuse. This 
technique requires HME to create a drug delivery platform which facilitates 
rapid drug absorption and the desired adverse effect. They have launched 
dosage forms which provide a solution to this problem. In addition, PADT 
technology prevents alcohol-induced dose dumping and alcohol extraction by 
maintaining sustained release characteristics in 40% alcohol, in comparison 
to the release in water or normal dissolution medium for more than 3 hrs 
(Andrews et al., 2009).  
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2.6.8. Regulatory concern  
Pharmaceutical formulations prepared using HME have been approved in 
the USA, Europe and Asia (Breitenbach et al., 2002). HME is a mature 
engineering technique which has full documentation to execute regulatory 
expectations. HME also provides information regarding different parameters 
such as torque, feed rate, pressure, segmental temperature, screw speed 
and melt pressure. These parameters can be monitored with probes and 
local sensors during processing. Enabled process analytical techniques 
(PAT) allow the in-line monitoring using different analytical techniques e.g. 
UV-Visible, Raman and N-IR. Such data can ensure the quality of a product 
and can simplify quality control.  
2.6.9. Advantages and limitations of HME 
2.6.9.1. Advantages  
Continuous process: Being a single step continuous technique, extrusion 
overcomes the problems associated with batch processes such as batch 
variability, wastage, time consuming and complicated processes. 
Solvent free: The technique is independent of water or solvent so it is an 
environmentally friendly and anhydrous method. 
High yield: The process has a high yield capacity and less wastage is 
associated with processing.  
Easily scalable: HME can be readily scaled from laboratory (bench top) to 
manufacturing scale. 
PAT: Extrusion facilitates PAT to monitor in-line processing to maintain 
quality of product. 
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Table 2.6 Advantages of HME 
Features Benefits 
Solvent free Environmentally friendly; economical; no 
residue in the final product 
Continuous process Fewer unit batches required; efficient 
scale-up from laboratory to large scale 
production 
Intense mixing and agitation achieved Improved content uniformity 
Compressibility not required Useful for powder with low 
compressibility index 
Polymers serve multiple purposes Less number of excipients required; cost 
effective 
Versatility  Sustained, modified, controlled and 
targeted release formulations 
Greater thermodynamic stability than 
that produced by other hot melt 
methods 
Less tendency towards recrystallisation 
2.6.9.2. Limitations 
The application of high temperature and shear can be major drawbacks in 
HME.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
A limited number of FDA approved polymers, flow properties of polymers and 
high energy requirements are limitations of the technique. However, these 
challenges can be overcome by engineering and formulation approaches. 
The selection of suitable polymers and the use of plasticizers can allow 
processing to be carried out at low temperatures. Appropriate control of 
parameters such as applied shear, temperature, residence time and screw 
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design can reduce the possibility of drug or polymer degradation by lowering 
the mixing intensity. 
2.6.10. Summary 
HME is a moderately innovative technology in the pharmaceutical industry. 
There are some concerns associated with HME such as high processing 
temperatures and high plasticiser load adversely affecting the stability of 
thermolabile drugs during processing. HME may offer intellectual property 
benefits and opportunities in the fields of sustained release formulations, 
bioavailability and solubility enhancement, taste masking and crystal 
engineering. This technology certainly appears to have an immense potential 
to transform the development and manufacturing of many new dosage forms 
and novel drug delivery systems.  
HME was selected for investigation during this research due to its versatility 
and potential usage with a wide range of pharmaceutical applications. Its use 
in forming polymeric formulations will be explored, together with novel solid 
state transformation.   
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3. Materials and Methods  
 
In this chapter, the materials, experimental procedures and characterisation 
methods used throughout the research are described in detail. The methods 
section is subdivided into two parts; methods used for processing 
thermolabile drugs using hot melt extrusion and those used for the 
generation of polymorphs using high temperature extrusion. The 
computational methodology adapted to investigate the stability of prepared 
crystal forms is also described. PCP Disso software, developed at Poona 
College of Pharmacy, Pune, India was used to analyse the dissolution 
results. The pharmacokinetic study was performed at C U Shah College of 
Pharmacy, SNDT University, Mumbai, India by me. The computational 
studies were perfomed with the help of Dr. John Kendrick.  A schematic 
presentation of the chapter is shown in figure 3.1.  
 
 
 
Figure 3.1 A schematic presentation of the chapter 
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3. 1. Materials 
A description of important equipment and materials used for this research is 
provided in this section. These include  
3.1.1. Drugs 
 Artemisinin, piracetam, chlorpropamide, carbamazepine, paracetamol and 
theophylline (All sources and lot numbers are lised in Table 3.1). 
Table 3.1 List of APIs, sources and their lot numbers 
APIs Source Lot no.  
Artemisinin Cipla Pharmaceuticals ART25062007 
Piracetam Sigma Aldrich  P5295 
Chlorpropamide Sigma Aldrich C1290 
Carmabazepine Sigma Aldrich C4024 
Paracetamol Sigma Aldrich A3035 
Theophylline Sigma Aldrich T1633 
 
3.1.2. Polymers 
 Soluplus® 
3.1.3. Chemicals and solvents  
Specifications of all the chemicals and solvents are summarised in Table 3.2.  
Table 3.2 Specification of drug, chemicals and solvents 
Drug/ Chemical/ 
Solvent 
Supplier Grade Lot Number 
Soluplus® BASF, Germany - HJ076 
Sodium lauryl 
sulphate  
Fluka 99.0%+ 71727 
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Ethanol Fisher Chemicals HPLC grade 724798, 856783 
Carboxymethyl 
cellulose 
Sigma Aldrich - F5832 
Acetonitrile Fisher Chemicals HPLC grade 1376894 
Methanol Fisher Chemicals HPLC grade 1758328 
Sodium hydroxide Sigma Aldrich ACS 97.0%+ 221465 
 
3.1.4. Equipments  
Specifications of all the equipment used in this research work are listed in 
Table 3.3.  
Table 3.3 Specification of equipments  
Equipments  Make Specifications 
Twin screw extruder Thermo Scientific, UK Pharmalab 16 mm co-
rotating 
Scanning electron 
microscopy 
 FEI (Cambridge, UK) Quanta 400 SEM 
DSC TA Instruments (Crawley, 
UK) 
Q2000 
PXRD Bruker (Billerica, USA) D8 powder diffractometer 
TGA TA Instruments (Crawley, 
UK) 
Q 5000IR 
Helium pycnometer Micromeritics (Atlanta, 
USA)  
AccuPyc 1330 
HPLC Agilent technologies 
(Wokingham , UK) 
1100 series 
HPLC-MS WatersAlliance (Milford, 
USA) 
separation module 2695 
GC-MS Agilent technologies 
(Wokingham , UK) 
7890A GC system 
Dissolution apparatus Copley Scientific 
(Nottingham, UK) 
USP-XXVI type 2 paddle 
test apparatus  
Hot stage microscope Linkam, (Tadworth, UK) Zeiss Axioplan-2 
microscope using a 
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Linkam 44 hot stage 
(THMS600) 
Shear cell  Linkam, (Tadworth, UK) CSS450 optical rheology 
system 
FTIR Digilab (Randolph, USA)  FTS 2000 spectrometer 
UV Agilent technologies 
(Wokingham , UK) 
Cary 50 Varian probe 
Rotational rheometer Anton Paar (Graz, Austria) Physica MCR 501 
Feeder Brabender technologies 
(Duisburg, Germany) 
Brabender Gravimetric 
Feeders 
3.1.5. Software  
The following table (Table 3.4.) details the software used in this work 
Table 3.4 List of all software used in the work  
Software  Purpose  
TA universal analysis Thermal analysis  
PowDLL converter  PXRD pattern analysis  
PCP Disso V3 Dissolution data  
Cary Win UV scan application version 
02.00(25) 
UV spectra 
Material Studio software 4.1.0 Computational predictions 
3.2. Methods used for the processing of a thermolabile drug using hot 
melt extrusion 
The following techniques were used for the physicochemical characterisation 
of pure artemisinin and prepared solid dispersions.  
3.2.1. Characterisation of pure drug and polymer 
3.2.1.1. Fourier transform infrared spectroscopy  
Samples for FTIR analysis were prepared by using the KBr disc method (1% 
samples). The prepared discs were analyzed at 25°C using a Digilab FTS 
2000 spectrometer (Randolph, USA) equipped with a deuterated triglycine 
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sulphate (DTGS) detector. A total of 128 scans were measured and an 
average spectra was recorded between 4000 to 600 cm-1 at a resolution rate 
of 4 cm-1.  
3.2.1.2. Thermo-gravimetric analysis 
The onset of thermal degradation was analysed using a TA Instruments 
Q5000 Thermo Gravimetric Analyser (Crawley, UK) equipped with a RSC90 
cooling unit. Each aluminium pan was calibrated before loading. 
Approximately 5 mg of sample was loaded into each aluminium pan and the 
pans were heated at a rate of 10°C/ min over the temperature range of 25 to 
200°C. An inert atmosphere was maintained by purging with nitrogen gas at 
a flow rate of 30 ml/min.  
3.2.1.3. Differential scanning calorimetry 
Differential Scanning Calorimetry (DSC) studies were carried out using a TA 
Instruments Q2000 (Crawley, UK) equipped with an RSC90 cooling unit. 
Indium standards were used to calibrate the DSC temperature and enthalpy 
scales. Approximately 4 mg of samples were hermetically sealed in an 
aluminium pan and a similar empty pan was used as a reference. The pans 
were heated at a constant rate of 10°C/ min over a temperature range of 25 
to 200°C. The inert atmosphere was maintained by purging with nitrogen at a 
flow rate of 50 ml/min.  
3.2.1.4. Powder X-ray diffractometry 
PXRD patterns were recorded using a Bruker D8 X-ray powder 
diffractometer with an X-ray wavelength of 0.154 nm, Cu source, 40 keV 
voltage and a filament emission of 40 mA. Samples were scanned from 2 to 
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30° (2θ) using a 0.01° step width and a 1s time count. The scatter slit was 
0.2° and the receiving slit was 1°. 
3.2.1.5. Ultra-Violet visible spectrophotometry 
The UV absorption spectrum of artemisinin was measured using a Cary 50 
Varian probe UV visible spectrophotometer (Wokingham, UK). Samples were 
prepared in ethanolic solution and the spectra were recorded with the range 
of 200 to 500 nm. Cary Win UV scan application version 02.00(25) software 
was used to record the spectra. A calibration curve for artemisinin was 
obtained using 10% (v/v) ethanolic water and 0.1% (w/v) sodium lauryl 
sulphate as a solvent. 5, 10, 15, 20, 25 and 30 µg/ml standard artemisinin 
solutions were prepared. One ml of artemisinin solution was treated with 
alkali by adding 2 ml of 0.2% (w/v) NaOH solution. All the mixtures were kept 
in a water bath at 50°C for 30 mins and the UV absorbance was recorded at 
290 nm.  The absorbance was then plotted against the respective 
concentrations in order to produce a calibration curve. 
3.2.1.6. Rotational rheometry  
The rheological behaviour of artemisinin, Soluplus® and physical mixtures in 
different ratios was studied using an Anton Paar Physica MCR 501, 
rotational rheometer (Graz, Austria), equipped with a temperature controlled 
furnace. Physical mixtures of artemisinin and Soluplus® were prepared in 
1:1, 1:3 and 1:5 ratios (w/w)  (50, 33.3 and 16.7% (w/w) respectively) by 
blending in a Turbula mixer for 10 min. Parallel plates of diameter 25 mm 
were used for rheological characterisation with the distance between the 
plates set to 1 mm. The polymer or physical mixture was added to the bottom 
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plate after the set temperature had been achieved. Upon melting, separation 
between the plates was reduced to the set experimental distance. The time 
dependent stability of melts were measured using a time-temperature sweep 
test. The test was performed at temperatures of 100, 110 and 130°C, at a 
fixed strain of 1% and a fixed frequency of 10 Hz for 30 minutes. The 
complex viscosity was measured every 5 seconds.  During rheological 
measurement, it was observed that there was some discolouration in the 
mixture after melting. The colour intensity increased with increasing 
concentration of artemisinin in the mixture. Therefore physical mixture 
containing 50% (w/w) artemisinin was only investigated for extrusion and 
product optimisation.   
3.2.2. Preparation of Solid Dispersions by Extrusion  
Extrusion was carried out using a co-rotating twin screw extruder 
(Pharmalab, Thermo Scientific, UK) with a screw diameter of 16 mm and a 
screw length to diameter ratio of 40:1. An extruder temperature profile of 
T110 was used (T110, as detailed in table 3.13) at a constant screw rotation 
speed of 50 rpm. The powder blend (10 g) was fed into the extruder at a rate 
of 0.12 kg/h using a gravimetric twin screw feeder (Brabender, Germany). 
Following extrusion, the extruded strand was air cooled and pelletised. The 
experimental set up is shown in figure 3.2.    
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Figure 3.2 Different views of Pharmalab co-rotating 16 mm twin screw 
extruder 
3.2.2.1. Extruder Screw Configurations  
Residence time has a significant impact on the quality of the extruded 
material, therefore two different screw configurations were employed. The 
following table (Table 3.5) describes the two different configurations 
employed in this experiment (figure 3.3).  
Table 3.5 Screw configurations  
(a: in terms of diameter   ID: 16 mm) 
A B 
Length (D)a Element Length (D)a Element 
8 Forwarding 28 Forwarding 
2.25 30° 2.25 30° 
1.25 60° 1.25 60° 
1 90° 1 90° 
6 Forwarding 6 Forwarding 
1.5 Discharge 1.5 Discharge 
20 Total length 40 Total Length 
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Figure 3.3 Extruder screw configurations 
3.2.2.2. Temperature Profiles  
In this study, extrusion was carried out using the optimum T110 temperature 
profile. This profile was selected from data obtained from rotational 
rheometry. The extruder barrel is divided into 9 different zones and the 
highest temperature was maintained at zone 7 as it encompasses the mixing 
section. The set temperature profiles are shown in Table 3.6.   
Table 3.6 Diagrammatic presentation of temperature profiles 
Temperature  
Profile  
Zone 2 3 4 5 6 7 8 9 Die 
T110 A - - - - 25 25 110 110 110 
T110 B 20 25 80 90 100 110 110 110 110 
3.2.3. Characterisation of extruded materials 
Extrudates were characterised using DSC and X-Ray diffractometry (as 
described above).  
3.2.3.1. Assay 
Solid dispersions equivalent to 20 mg of artemisinin were weighed accurately 
and dissolved in a suitable quantity of medium containing 10% (v/v) ethanolic 
water and 0.1% (w/v) sodium lauryl sulphate. An appropriate quantity was 
treated with alkali using 0.2% (w/v) NaOH. The drug content was measured 
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at 290 nm using a UV spectrophotometer. Analysis of data was performed 
using PCP-Disso software (Poona College of Pharmacy, PCP Disso V3, 
Pune, India). 
3.2.3.2. In-vitro Dissolution  
In-vitro dissolution studies were performed using a USP-XXVI type 2 paddle 
test apparatus (Copley Scientific, Nottingham, UK). Powder samples 
equivalent to 20 mg of artemisinin were placed in dissolution vessels 
containing 600 ml of dissolution medium maintained at 37°C ± 0.1°C and 
stirred at 100 rpm. The dissolution medium consisted of ethanol 10% 
ethanolic water and sodium lauryl sulphate (0.1% w/v). Samples were 
collected periodically and replaced with fresh dissolution medium. The 
collected sample was filtered using a cellulose acetate filter and treated with 
alkali. The concentration of artemisinin was determined 
spectrorphotometrically at 290 nm.  The dissolution profiles were generated 
using PCP Disso software V3 (Poona College of Pharmacy, Pune, India). 
3.2.3.3. Pharmacokinetic Study 
Study protocol 
A study was performed with prior approval from the IAEC of C U Shah 
College of Pharmacy, whose guidelines were followed throughout the 
studies. 36 healthy albino wistar rats with a weight 180-200 g were taken and 
divided into three groups; control, pure drug and solid dispersion. A sparse 
technique was used to collect blood samples (n=6). The animals were 
housed in standard metabolism cages and fasted for 12 hours before dosing 
but allowed free movement and access to water throughout the experiment. 
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100 mg of artemisinin was dispersed in 0.5% (w/v) aqueous CMC solution 
and the oral dose (equivalent to 100 mg of artemisinin) was administered 
using an oral syringe. At predetermined time intervals, blood samples were 
obtained by the retro orbital technique and collected in EDTA tubes.  
Sample analysis 
Plasma was obtained by centrifugation of the blood sample at 3500 rpm for 
15 mins. A volume of 200 µl plasma was pipetted into Eppendorf tubes and 
100 µl of internal standard (artemether solution 1000 µl/ml) and 700 µl 
methanol were added. The solution was vortexed for 2 minutes and the 
organic phase was separated by centrifugation. The collected sample was 
then subjected to analysis by HPLC (Agilent technologies, 1100 series, 
Wokingham, UK). The plasma level of artemisinin was analysed by HPLC 
using 65% acetonitrile and 35% water as the mobile phase. The HPLC 
system consisted of an Agilent 1200 series, UV detector set at 210 nm and a 
C18 column (250 x 4.6 mm). Artemisinin exhibits a maximum UV absorption 
at 210 nm.  The limits of detection and quantification were 1.01 and 3.06 
µg/ml, respectively. The concentration against peak area graph plot was 
found to be linear (r2 = 0.998).   
3.2.3.4. Stability  
All extruded materials were stored at room temperature and their stability 
was studied at intervals of 1 month, 3 months, 6 months, 9 months and 12 
months by PXRD and dissolution using the above methods.  
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3.3. Methods used for polymorphic transformation 
3.3.1. High temperature extrusion   
The commercially available forms of drugs were processed in a twin screw 
extruder (Pharmalab, ThermoScientific, UK with screw diameter 16 mm and 
length to diameter ration 40:1) at different set temperatures, below the 
melting point of the respective drugs. Screw rotation speeds of 10, 20 and 30 
rpm were used to investigate the effect of shear and residence time on the 
product. The screws were configured to produce low, medium and high 
shear intensity. Full details of the screw configurations, temperature profiles 
and screw speed are displayed in Table 3.7.  
Table 3.7 Full details of extrusion experiments with different applied 
parameters 
Drug Temperature Profiles Screw Speed Configuration  
Artemisinin T130, T140 20 and 30 rpm A, B, C 
Piracetam T130 10 rpm C 
Chlorpropamide T115 10 rpm C 
Carbamazepine T145 10 rpm C 
Theophylline T120, T150 10 and 30 rpm A, B, C 
Paracetamol T130, T150 10 and 30 rpm A, B, C 
Glycine T115, T130 10 and 30 rpm A, B, C 
3.3.1.1. Extrusion Temperature profiles  
Full details of temperature profiles are illustrated in Table 3.8.  
Table 3.8 Details of temperature profiles 
Profile Zone 2 3 4 5 6 7 8 9 10 
T130 20 60 80 120 120 125 125 130 130 
T140 20 60 80 140 140 140 140 140 140 
T115 20 60 80 100 110 115 115 115 115 
T145 20 60 80 145 145 145 145 145 145 
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T130 20 60 80 130 130 130 130 130 130 
T120 20 60 80 120 120 120 120 120 120 
T150 20 60 80 150 150 150 150 150 150 
3.3.1.2. Screw configurations 
Full details of screw configurations A (low shear intensity), B (medium shear 
intensity) and C (high shear intensity) are displayed in table 3.9.  
Table 3.9 Extruder Screw configurations 
A B C 
Length 
(D)a 
Element Length (D)a Element Length (D)a Element 
28 Forwarding 11 Forwarding 6 Forwarding 
2.25 30° 1 30 2 90° 
1.25 60° 1 60 1 60° 
1 90° 1 90 6 Forwarding 
6 Forwarding 6 Forwarding 1.25 60° 
1.50 Discharge 1.5 30 4 Forwarding 
40 Total 
Length 
8 Forwarding  1 90° 
  1 60 1 60° 
  2 90 1.25 30° 
  6 Forwarding 4 Forwarding 
  1.5 Discharge 1 60° 
  40 Total 
Length 
1 30° 
    9 Forwarding 
    1.50 Discharge 
    40 Total 
Length 
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3.3.2. Crystallisation of artemisinin polymorph  
A re-crystallisation technique was used to prepare the triclinic form of 
artemisinin (Chan et al., 1997). It was performed in a 500 ml conical flask. 
The temperature of the reaction vessel was maintained at 80°C by 
recirculating water. The orthorhombic form of artemisinin (20g) was added in 
50 ml of cyclohexane. The supersaturated mixture was then heated for 1 hr 
at 80°C along with continuous stirring. The temperature was decreased by 
10°C every 30 minutes until the solution temperature reached 30°C. After a 
few minutes, stirring was stopped and the triclinic form was isolated, vacuum 
dried and stored in an air tight container. The determined recovery was 
approximately 13g.  
3.3.2.1. Characterisation of the prepared crystals  
The prepared crystals were characterised using DSC, FTIR and X-Ray 
diffractometry (as described above). 
Gas Chromatography- Mass Spectrometry (GCMS)  
GC-MS was performed to calculate the amount of residual solvent using 
Agilent technologies 7890A GC system and the following method was used.  
Preparation of stock solution  
Cyclohexane (200 mg) was weighed accurately and transferred to 100 ml 
volumetric flask. This was mixed with 15 ml dimethylformamide (DMF) and 
diluted to the volume with DMF. 1 ml of above stock solution was transferred 
to 50 ml volumetric flask and dissolved in 25 ml DMF and further diluted with 
DMF.  
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Preparation of sample solution  
Samples (500 mg) were accurately weighed and transferred to a 50 ml 
volumetric flask. They were then dissolved in 30 ml of DMF and were further 
diluted with DMF.   
Chromatographic conditions are listed in Table 3.10.  
Table 3.10 Chromatographic conditions 
Gas Chromatograph  
Column Rtx®-624, 30 m, 0.32 mm ID, 1.80 
µm (cat.# 10970) 
Injector Temperature 150°C 
Carrier gas  Helium 
Detector Temperature 240° C 
Injector Mode Split less 
Split Ratio  NA 
Oven Temperature  40° C 
Initial Time  10 min 
Rate   10 °C 
Final Temperature  240 ° C 
Final Time  10 min 
Injection volume 1µl 
Carrier Gas He, constant flow 
Flow Rate 2.16 mL/min 
Linear Velocity 35.3 cm/sec 
Detector FID @ 260°C 
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3.3.3. Characterisation of extruded samples 
Extruded samples were analysed by DSC and PXRD as described above.  
3.3.3.1. High Performance Liquid Chromatography - Mass Spectrometry 
(HPLC-MS) 
HPLC was performed using a WatersAlliance separation module 2695 
(Milford, USA). Column C18, 3 x 100 mm, 1.8 um particle size was used and 
1ul of artemisinin was loaded. 50% acetonitrile, 50% water, 0.09% formic 
acid and 0.01% trifluroacetic acid was used as a mobile phase.  
3.3.3.2. Density measurement 
True density of the samples was measured using a Micromeritics AccuPyc 
1330 Helium Pycnometer (USA). An empty cup of volume 10 cm3 was 
initially analysed to confirm that the value of the average volume was zero; 
the error was found to be less than 0.05%. The instrument was calibrated 
using a calibration standard metal ball with a known volume of 6.372882 
cm3. Helium gas (99.995% pure) was passed under a pressure of 20 psig 
with an equilibrium rate of 0.005 psig/ min at a temperature of 25°C ± 2°. 
Following the calibration, a known mass of sample was added to the cup. 
Samples were analysed in triplicate and an average density was calculated.  
3.3.3.3. Scanning electron microscopy (SEM) 
Samples were mounted on aluminium pin-stubs (Agar Scientific, Stansted, 
U.K.) for SEM using self-adhesive carbon mounts (Agar Scientific). Scanning 
electron microscopy was performed using a Quanta 400 SEM (FEI 
Company, Cambridge, UK) in a high vacuum operated at an acceleration 
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voltage of 20 kV. XTM Microscope control software version 2.3 was used for 
imaging. 
3.3.3.4. Pharmacokinetic study 
The same pharmacokinetic study was performed for the prepared polymorph 
as described previously (3.2.3.3.).  
3.3.3.5. Mechanical understanding of high temperature extrusion 
process 
Hot stage microscopy and shear were used to illustrate the mechanism of 
polymorphic transformation during the high temperature process.  
Hot stage microscopy (HSM) 
Microscopy was performed using a Zeiss Axioplan-2 microscope equipped 
with a Linkam 44 hot stage (THMS600) (Tadworth, UK). The data was 
visualised using Axiovision (4.5) software with the linksys 32 patch for hot 
stage control. The sample was isothermally treated at 140°C for 90 min at a 
heating rate of 10°C/min. Images were captured at different intervals.  
Shear Cell 
Shear cell microscopy (displayed in figure 3.4) was performed using a 
Linkam shear cell (CSS450) coupled with a polarised light microscope 
connected to a video capture system. The sample was loaded between the 
top and bottom of highly polished quartz windows of the shear cell and the 
gap between the two plates was reduced to 30 µm by slowly lowering the 
upper glass plate of the Linkam device. The sample was isothermally heated 
at 140°C for 15 min and the steady shear rate was maintained at 0.5 s-1. 
Images were captured using a digital camera.  
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                             Figure 3.4 A model shear cell 
3.3.4. Computational Techniques 
Computational chemistry is able to generate complementary data to 
experiments, based upon the structures, properties and reactions of 
materials. It involves the application of mathematical, computing and 
chemical skills to solve interesting chemical problems. It can assist the 
experimental chemist to predict the results before running the actual 
experiment or it can challenge the experimental chemist to find entirely new 
chemical entities. It can also be a useful tool to investigate compounds which 
are very difficult to generate and expensive to purchase. The increasing 
interest in computational techniques for structure and physicochemical 
property prediction of molecules has become a vital tool in chemical 
research. Recently the pharmaceutical industry has been attracted to these 
computational techniques because drug discovery and efficacy depends on 
the surface activity of active pharmaceutical ingredients and excipients.               
Quantum mechanics and molecular mechanics are the foundation of most 
computational techniques. Quantum mechanical theory is commonly used for 
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accurate simulations of atomic and molecular systems. It can be based on 
the time dependant Schrӧdinger equation associated with the molecular 
Hamilton. Although this technique describes molecular structure very 
accurately, it is computationally very expensive therefore is applicable only to 
the smallest systems or to small molecules. Even with the most powerful 
computers available today, calculations on large systems are beyond the 
reach of quantum mechanics. Another major limitation of quantum 
mechanics is the calculation of the electronic energy for a given nuclear 
configuration.  
Molecular mechanics describes the total energy of the system as a sum of 
analytical terms representing bonding and non-bonding interactions. The 
advantage of molecular mechanics is that it allows for the modelling of a 
wide range of molecules including segments of DNA and proteins; making it 
a primary tool for a computational biochemist. The main benefit of molecular 
mechanics is the speed at which modelling or calculations can be performed.  
Molecular mechanics depends on the accuracy of the force field. A force field 
is a description of the potential energy surface, which is a function of the 
geometry of the molecule or set of the molecules. Various force fields have 
been developed over the years for modelling purposes. Some force fields 
account for coupling between bending and stretching in adjacent bonds in 
order to improve the accuracy of the mechanical model. A force field for 
molecular mechanics is designed from the following principles:  
 Nuclei and electrons are lumped into atom-like particles 
 Atom-like particles are spherical and have a net charge  
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 Interactions are based on springs and classical potentials 
 Interactions are pre-assigned to specific atom types 
 Interactions determine the spatial distribution of atom-like particles 
and their energies 
The quality of a force field calculation relies on the suitability of the 
mathematical form of the energy expression and the accuracy of the 
parameters. Force field methods are investigated mainly to predict 
geometries and relative energies of the molecules. For systems where 
accurate parameters are available, it is possible to make a very good 
prediction of geometries and relative energies of a large number of 
molecules in a short space of time (Goodman, 1998 and Jensen, 1999). In 
general, structural features are relatively easier to predict compared to 
relative energies. Validation of a force field is commonly made by proving 
how accurately it reproduces reference data that may or may not have been 
employed in the actual parameterisation.  
Different molecular modelling software packages are commercially available. 
Materials Studio is an example of such software. It comprises a suite of 
molecular modelling software packages from Accelrys Inc., San Diego, CA. 
designed to allow researchers in the field of material science and chemistry 
to predict and understand the correlation between the atomic and molecular 
structure of a material with its physicochemical properties. It has been widely 
used in various industries such as pharmaceutical, polymer, metal, 
composites, catalysts, fuel and batteries. The 'Visualiser' is a graphical user 
environment in which the researcher can construct, manipulate and view 
models of molecular structures. It offers different modelling modules and the 
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researcher has to pick a specific module for a desired requirement, 
combining it with the Visualiser.   
In this work, Material Studio software was used to understand the stability of 
the prepared polymorphs computationally.  
3.3.4.1. Crystal structures 
3D crystal structures of both polymorphs were obtained from the Cambridge 
Structural Database (CDS) with codes QNGHSU (orthorhombic) and 
QNGHSU01 (triclinic). These structures were used to develop and validate 
the force field which was used for further calculations of the morphology 
prediction and the adsorption energies using the morphology and the 
sorption modules in Material Studio software 4.1.0.   
3.3.4.2. Geometry optimisation  
Geometry optimisation refines the geometry of a structure until it satisfies 
specific criteria. It is an interactive practice in which the atomic synchronises 
and the cell parameters are customised until the total energy of the structure 
is minimised. Hence, the optimised structure relates to a minimum in the 
potential energy surface. Geometry optimisation was performed using 
Universal, CVFF, PCFF and Dreiding force fields with built in and 
equilibrated charges (QeQ) from a Forcite module. Calculated values were 
then compared with experimental values. Forcite is a classical molecular 
mechanics module that allows fast energy calculations and reliable geometry 
optimisation of the molecules. Forcite is designed to work with a wide range 
of forcefields, and provide easy and flexible access to the associated 
parameter options. 
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3.3.4.3. Morphology prediction  
The Morphology module predicts the external morphology of a crystal from 
the atomic structure of a crystal. The crystal habit is critically important for 
the pharmaceutical and industrial processing of solids. There are different 
examples in the pharmaceutical and chemical industries where the crystal 
shape may have influenced the dissolution rate and bioavailability of the drug 
stability, density and processability. Therefore chemists, chemical and 
process engineers are interested in crystal morphology and its relation to the 
internal atomic arrangement. This relationship enables prediction of crystal 
shape and the effect of different solvents and additives. This tool has 
significant applications in the pharmaceutical, food science, cement, 
agrochemical, commodity and petrochemical industries.  There are many 
methods to deduce a crystal habit, such as Bravais - Freidel - Donnay - 
Harker (BDTH), Growth morphology and Equilibrium morphology.  
Table 3.11 Principle of different morphology modules  
Morphology  Principle  
Bravais - Freidel - Donnay - Harker 
(BDTH) theory  
The BDTH method is a geometrical 
calculation which uses the crystal lattice 
and symmetry to generate a list of 
possible growth faces and their relative 
growth rates. 
Growth Morphology The Growth morphology presumes that 
the growth rate of a crystal face is 
proportional to its attachment energy.  
Equilibrium Morphology The equilibrium morphology of a crystal 
is calculated by the minimum of the 
surface energies for all relevant crystal 
faces.  
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The BDTH, Growth morphology and Equilibrium morphology method within 
Material Studio Software 4.1.0 was used to predict the crystal morphology.  
3.3.4.4. Sorption  
The sorption module offers a solution for the prediction of molecular 
adsorption on the surface of crystalline material.  Molecular adsorption into 
microporous structures such as zeolites, alumino hosphates, or polymers is 
essential in several applications including hydrocarbon cracking, air 
separation, ion exchange and gas sensors. The sorption module simulates a 
pure adsorbate in a sorbent framework by using the Metropolis Monte Carlo 
method. 
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4. Processing of a thermolabile drug using hot melt extrusion 
Pharmaceutical hot melt extrusion involves the processing of a drug and 
polymer in a molten state under shear applied by rotating screws. High 
processing temperatures can limit its application for some thermolabile APIs. 
Processing temperature can be reduced using plasticisers, but this can 
significantly increase the bulk of the formulation. Here, Soluplus®, a polyvinyl 
caprolactum-polyvinyl acetate-polyethylene glycol graft co-polymer which 
has low Tg and good extrudability, was selected. Artemisinin, a keystone of 
malaria treatment recommended by the World Health Organisation (WHO) 
was used as a model thermolabile API. The well-known problem associated 
with artemisinin is its poor aqueous solubility. In addition, it provides a 
processing challenge due to its thermolabile nature. The lactone ring of 
artemisinin degrades in basic pH, thus a weak acid (citric acid) was used to 
maintain a neutral pH. A schematic presentation of the chapter is shown in 
figure 4.1.  
Figure 4.1 A schematic presentation of the chapter 
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4.1. Introduction 
Hot melt extrusion (HME) has been widely used in the pharmaceutical 
industry to prepare solid dispersions with the aim of improving the 
bioavailability of poorly water soluble drugs (Luener et al., 2000). During the 
processing of solid dispersions by HME, the hydrophobic drug is processed 
with a thermoplastic polymer in a molten state to obtain a stabilised 
amorphous form to achieve enhanced aqueous solubility. In HME, the 
selection of a suitable polymer plays a vital role in the formulation as well as 
in setting extrusion conditions. Typically the extrusion process should be 
carried out at 20-40°C above the glass transition temperature (Tg) of the 
polymer. The ‘extrudability’ of a polymer can be determined by its glass 
transition and its rheology (Chokshi et al., 2005). Exposure of material to 
high temperatures is one of the major concerns during HME, as this may 
adversely affect the drug stability especially for thermolabile drugs. High 
processing temperatures can limit the processing of thermolabile drugs 
(Thumma et al., 2005) and high temperature HME processing is not suitable 
for a number of APIs due to thermal decomposition which may result in the 
loss of pharmacological activity (Follonier et al., 1994). In such cases, 
plasticisers may be added to the pure polymer in order to lower the Tg and 
melt viscosity, allowing extrusion to be performed at lower temperatures 
(Ghebremeskel et al., 2007 and Repka et al., 2008). Lowering the processing 
temperature reduces drug degradation and facilitates drug stability in 
pharmaceutical formulations. Repka et al. formed films containing the 
thermolabile drug hydrocortisone in hydroxypropyl cellulose by incorporating 
high levels of plasticisers during melt extrusion (Repka et al., 1999). 
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Generally, plasticisers are used in a concentration range of 5-30 % w/w of 
the extrudate. The use of plasticisers in pharmaceutical formulations has 
some disadvantages, such as plasticisers with low molecular weight may 
volatilise and contribute to internal pollution; this phenomenon is known as 
‘sick house syndrome’. Plasticisers contribute to the bulk of the dosage form 
and therefore lower the adhesive strength of the product. They can also 
adversely affect the mechanical properties, drug release and stability of the 
product as well as cause bubble formation. In the last 10 years, a new 
technique was adapted from the polymer industry using a combination of 
pressurised gases with processing (Tomasko et al., 2003). The injection of 
supercritical CO2 leads to the swelling and modifying of the polymer’s 
mechanical and physical properties. In addition, the carbon dioxide acts as a 
plasticiser and reduces the glass transition temperature. Verreck et al. 
investigated the use of CO2 as a foaming and reversible plasticiser, through 
its reducing chain-chain interactions and increasing the inter-chain distance, 
and its effect on thermal properties and performance of an itraconazole solid 
dispersion (Verreck et al., 2007). However, the application of supercritical 
CO2 in HME increases the cost of production in comparison with the 
conventional method.  
Therefore, there exists a requirement for development of a more suitable 
approach to facilitate the processing of heat sensitive drugs which is one of 
the main objectives of this work.  
Artemisinin, a keystone of malaria treatment, is isolated from the Chinese 
herb Artemisia annua L. and is recommended by the World Health 
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Organisation (WHO) as part of a combination therapy. Artemisinin has low 
bioavailability and poor water solubility. Artemisinin is a widely used 
antimalarial drug which has poor water solubility and a thermolabile nature. It 
exhibits two crystal forms; a commercially available orthorhombic form and a 
less stable triclinic form. Therefore artemisinin has been selected as a model 
drug to explore the application of hot melt extrusion to prepare solid 
dispersions of thermolabile drugs and cause solid state polymorphic 
transformation.   
Artemisinin was extracted from the herb Artemisia annua L. and analysed by 
Chinese scientists in 1972. It was proven to be effective against plasmodium 
falciparum as well as cerebral malaria (Charles et al., 1990). Artemisinin is a 
polycyclic sesquiterpeneendoperoxide. The peroxide group within it is 
fundamental for anti-malarial activity. It blocks a free heme released by the 
parasite and converts it into hemozoin which helps to create proteins to kill 
the parasite (Eckstein et al., 2003 and Kannan et al., 2002). Additionally, it 
has a very low toxicity in the standard therapeutic dose (Koch et al., 1981 
and Luo et al., 1987). The molecular structure of artemisinin is displayed in 
figure 4.2 and a detailed profile of artemisinin is displayed in Table 4.1. 
 
Figure 4.2 Molecular structure of artemisinin 
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Table 4.1 Physicochemical properties of artemisinin 
Chemical Name (3R,5aS,6R,8aS,9R,12S,12aR)-
Octahydro-3,6,9-trimethyl-3,12-epoxy-
12H- pyrano[4.3-j]-1,2-benzodioxepin-
10(3H)-one 
Molecular Formula C15H22O5 
Molecular weight 282.3 g 
Melting Point 152-157°C 
Description White crystalline powder or colourless 
needles 
Solubility Practically insoluble in water, very soluble 
in dichloromethane, freely soluble in 
acetone,  soluble in ethanol and methanol 
Storage 0-5°C 
Artemisinin has poor aqueous solubility, which results in low and 
unpredictable absorption after oral administration; thus limiting its therapeutic 
applications. Moreover, it has a short half life and a high first pass 
metabolism which often leads to incomplete parasite clearance (Titulaer 
et.al., 1991).  
In the present study, artemisinin was selected as a model drug due to its 
thermolabile nature. This poses significant processing challenges for the 
formation of solid dispersions (Chen et al., 2008).  
A novel amphiphilic copolymer, Soluplus® (polyvinyl caprolactum polyvinyl 
acetate polyethylene glycol) was chosen to form solid dispersions with 
artemisinin, as it has the ability to enhance the solubility of poorly water 
soluble drugs and is suitable for melt extrusion below 120°C without the need 
for the incorporation of an additional plasticiser (Ali, 2010).  
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Soluplus®, a commercially available copolymer developed by BASF, is a   
polyvinyl caprolactum polyvinyl acetate polyethylene glycol in the form of 
white to yellowish free flowing granules with a slight characteristic odour. 
Because of its amphiphillic behaviour, it can either act as a carrier to form 
solid dispersions or solid solutions. The molecular structure of soluplus® is 
displayed in figure 4.3.  
 
Figure 4.3 Structure of Soluplus® Polymer 
Soluplus® is freely soluble in water. The following table (Table 4.2) indicates 
the solubility of Soluplus® in different solvents: 
Table 4.2 Solubility of Soluplus® in different solvents 
 
Solvent Ratio 
Water Any 
Acetone Up to 50% 
Methanol Up to 45% 
Ethanol Up to 25% 
Dimethylformamide Up to 50% 
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Applications  
Recommended for Extrusion 
Soluplus® has a glass transition temperature of 70° C. It is suitable for 
extrusion and can be used in the processing range of 120 to 180°C without 
any additional plasticizer. It is reported that, a solid dispersion of fenofibrate 
and itraconazole can be made with Soluplus® at 100°C and 150°C 
respectively, keeping screw speed at 200 rpm, feed rate at 1kg/hr using a 16 
mm twin screw extruder.  
Features of Soluplus® 
 General: It can be used as an emulsifying agent or binding agent for 
wet granulation and act as a dry binder for direct compression.  
 Solubility enhancer: It can act as a solubility enhancing hydrophilic 
polymer for poor aqueous soluble drugs.  
 Drug loading onto nonpareils: A solution of drug and Soluplus® into 
organic solvents such as ethanol or acetone is able to form layering 
on sugar strand or nonpareil by spraying.  
The aim of this work was to investigate solid dispersion formulations of 
artemisinin and Soluplus® using HME, with a focus on processing 
challenges, product stability and biopharmaceutical performance.  
4.2. Result and discussion 
4.2.1. Material characterisation  
Materials were analysed using FTIR, TGA and DSC. 
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4.2.1.1. Fourier Transform Infrared Spectroscopy (FTIR) 
The structural determination and confirmation of an API is an important part 
of raw material analysis. The infrared absorption spectrum of artemisinin was 
obtained using an infrared spectrometer.  
Artemisinin is a complex molecule resulting from the fusion of rings, which 
are, apart the methyl substituents, bicycle, lactone and cyclohexane, for a 
total number of 42 atoms (Moroni et al., 2008). Artemisinins shows standard 
FTIR peaks (displayed in figure 4.3) at 928 cm-1, 1137cm-1and a strong band 
at 1760 cm-1 (lactone ring C=O) (Lin et al., 1985). 
 
Figure 4.4 FTIR spectra of pure artemisinin 
4.2.1.2. Thermo Gravimetric Analysis (TGA) 
In extrusion, processing is performed at an elevated temperature and 
therefore, it is necessary to determine the onset of degradation of the API 
and polymer. Thermo-gravimetric analysis was carried out to determine the 
onset of degradation of pure artemisinin and Soluplus® (shown in figure 4.5).  
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Figure 4.5 Thermo-gravimetric analysis of artemisinin and Soluplus® 
The above thermogram illustrates that the onset of degradation of pure 
artemisinin started at 160°C. Above 170°C, rapid degradation of artemisinin 
was observed which is represented by rapid weight loss. The degradation of 
artemisinin was found to be 15.73% from 170°C to 200°C whereas 
Soluplus® demonstrated thermal stability up to 200°C. Soluplus® showed 
the presence of moisture at a level of 2-5% (w/w). 
4.2.1.3. Differential scanning calorimetry (DSC) 
DSC thermograms of artemisinin, Soluplus® and their physical mixtures are 
shown in figure 4.6. Artemisinin exhibited a major endotherm at 154.81°C 
and Soluplus® exhibited a Tg at 70°C whereas the physical mixture showed 
a Tg at 80°C with a sharp endotherm at 154.75°C. From the DSC screening, 
temperatures of 100, 110 and 130°C were selected for rheology testing.   
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Figure 4.6 DSC thermograms of Soluplus (a), artemisinin (b) and physical 
mixture (c). 
 
4.2.1.4. Rotational rheology 
At a preformulation stage, the polymer is selected on the basis of drug-
polymer miscibility, glass transition temperature and the rheology of the 
mixture in its molten state. These properties may be tailored by the addition 
of a plasticiser, or by designing novel polymers of an amphiphillic nature and 
suitable extrudability such as Soluplus®. Screening at the preformulation 
level generally involves thermal analysis, rheological testing, miscibility 
predictions using a Flory–Huggins approach and hot stage microscopy (Tian 
et al., 2013 and Lakshman et al., 2008).  
The rotational rheometer is a device which can be used for studying the 
thermal compatibility of a drug and a polymer under controlled shear. It has 
been widely used in polymer research to study polymer flow. It enables the 
structural dynamics of complex fluids to be directly monitored at the same 
time as they are under precisely controlled temperature and a variety of 
-16
-14
-12
-10
-8
-6
-4
-2
0
2
20 60 100 140 180
H
e
a
t 
fl
o
w
 (
W
/g
) 
Temperature (⁰ C) 
Artemisinin
Soluplus
Physical Mixture
(50%)
Chapter 4: Processing of a thermolabile drug using hot melt extrusion 
 
NOVEL FORMULATIONS OF A POORLY SOLUBLE DRUG USING THE EXTRUSION PROCESS
 Page96 
 
shear modes. In this project, a rotational rheometer was used as a screening 
tool for optimising processing temperatures, drug loadings and to understand 
the effect of additives under shear.    
API and polymer interaction was also evaluated using rotational rheometry. 
Samples may undergo structural changes when subjected to high 
temperature and shear with respect to time. This may affect the viscosity of 
the formulation and these changes can be monitored using a ‘time sweep’ 
test. Furthermore, the polymer and API may undergo time dependent 
degradation at high temperatures, therefore the data obtained from this test 
can be correlated with typical HME residence times. Ideally, the viscosity of 
the polymer should remain constant at low shear rates for a given 
temperature; changes in viscosity may indicate structural changes in the 
material. 
 
Figure 4.7 Time dependent complex viscosity 
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From the DSC data, three temperatures were selected for the shearing 
experiments: 100, 110 and 130°C. However, the experiment could not be 
performed below 110°C as the material would not flow in the rheometer. The 
complex viscosity of the polymer with different drug loadings for time 
dependent tests at 110° C and 130°C are shown in figure 4.7. For pure 
Soluplus®, the viscosity is seen to be stable for 20 minutes at 110°C and 
130°C. The plasticising effect of artemisinin can be clearly observed as a 
drop in the complex viscosity with increasing drug loading. At a high drug 
loading of 50%, a drop in viscosity at these low angular frequencies 
combined with the visual observation of the treated material suggests that 
degradation had occurred. No discolouration was observed when Soluplus® 
and artemisinin were separately subjected to rotational rheometry tests at a 
temperature of 130°C. This indicates that an interaction between Soluplus® 
and artemisinin leads to the observed degradation during shearing at 130°C. 
The level of applied shear was found not to influence the discolouration.  
Thermal and rheological studies of artemisinin and Soluplus® provided some 
insight into artemisinin - Soluplus® compatibility issues which have been 
taken into consideration for further experiments. The important information is 
sumerised below: 
a. Pure Soluplus® does not show any discolouration at 130°C. Thermal 
analysis has shown that artemisinin is stable up to 160°C, and the 
treated sample in the TGA pan did not show any colour change. 
Therefore, there is an interaction between Soluplus® and artemisinin 
when subjected to high temperature. The DSC thermogram of the 
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physical mixture did not show any thermal events. Similarly, the TGA 
thermogram of the physical mixture containing 50% drug loading 
between the temperature range of 20-50°C, and isothermal TGA 
carried out at 110°C and 120°C for 30 minutes, did not show any 
significant weight loss other than moisture loss (shown in figure 4.8 
and 4.9) respectively.  The TGA sample of the physical mixture (1:1) 
after heating upto 200°C showed slight discolouration. It is important 
to understand if shear has enhanced this discolouration process.  
 
Figure 4.8 Thermo-gravimetric analysis of physical mixtures 
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Figure 4.9 Isothermal thermo-gravimetric curves for 50% physical mixtures at 
110⁰ C and 120⁰ C for 30 minutes 
b. The rheological measurements involved heating pure Soluplus® and 
physical mixtures of Soluplus® and artemisinin to high temperatures 
under different shear conditions. This study was used to investigate 
discolouration separately from rheological measurements. It was 
observed that the Soluplus® sample did not show any discolouration 
whereas the physical mixture samples showed a change in colour in 
all cases during rheological measurements. The samples measured at 
110°C were less intense in colour as those samples processed at 
130°C. The shear intensity did not have any significant effect on the 
colour and the colour intensity of the samples increased with an 
increase in drug loadings. The colour change was found to occur 
approximately after 10 minutes of shear application. This clearly 
indicates that there is some interaction between the drug and polymer 
which causes discolouration. It also suggests that the intensity of 
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discolouration increases with temperature and may increase with time 
too.  
c. It is reported that even though artemisinin itself is acidic in nature, it 
contains a sesquiterpene lactone ring with an unusual peroxide bridge 
(Eckstein et al., 2003). The sesquiterpene lactone ring undergoes 
electrochemical reduction at a basic pH. It was necessary to check if 
the moisture present in the polymer was producing a 
microenvironment with a basic pH which may cause degradation. The 
pH of the pure Soluplus® slurry was found to be 7.5. Soluplus® 
contains 2-5% (w/w) moisture which may provide an alkaline 
microenvironment, caused by the Soluplus® dissolving, leading to 
degradation. Therefore, it was decided that adding citric acid to the 
drug and polymer mixture may reduce the pH and reduce the number 
of heavy metal ions which could also potentially be responsible for the 
discolouration.  
d. Rheology experiments were carried out with the addition of 2-5% 
(w/w) citric acid to the 1:1 physical mixture with the highest colour 
intensity. It was observed that there was no discolouration for the 
samples containing 5% citric acid but discolouration was not 
prevented by 2% (w/w) citric acid. This indicates that citric acid could 
have prevented discolouration by avoiding the exposure of artemisinin 
to an alkaline microenvironment. When the physical mixture (1:1), 
containing 5% citric acid, was processed at 110°C, there was a 
decrease in the complex viscosity for the initial 3 minutes, followed by 
the viscosity remaining constant (shown in figure 4.10). An attempt 
Chapter 4: Processing of a thermolabile drug using hot melt extrusion 
 
NOVEL FORMULATIONS OF A POORLY SOLUBLE DRUG USING THE EXTRUSION PROCESS
 Page101 
 
was made to record the spectrum of the coloured sample in water and 
in ethanol separately over the UV and visible range but it did not 
exhibit any absorption.   
 
 
Figure 4.10 Time dependent complex viscosity of physical mixture 
containing 5% citric acid 
 
e. Another approach which was adapted during extrusion was to reduce 
the screw length which automatically reduce the residence time and 
shear applied during processing. The results from this study are 
discussed in the next sections. The extrusion studies were conducted 
at 110°C,  with a 1:1 (w/w) artemisinin : Soluplus® composition  
f. It was important to study if there is a significant reduction in drug 
content as a result of processing. Artemisinin does not contain a 
chromophore, hence it was difficult to select a sensitive and 
appropriate analytical method. A UV method was selected which 
involved the post derivatisation. The details of the calibration curve 
development are as follows: 
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The UV method was based on the formation of an alkali salt of artemisinin 
(Q292) (shown in figure 4.11) formed by treatment with 0.2% NaOH at 40°C, 
however the product was not coloured (Wright, 2002).  
 
Figure 4.11 Interaction of artemisinin with NaOH 
Artemisinin is highly reactive with alkalis such as NaOH and KOH, it reacts 
with 0.2% NaOH and forms an alkali salt (Q292) which is stable for up to 5 
hours. This method is specific for artemisinin and it does not react to other 
artemisinin derivatives such as dihydroartemisinin, artemether and 
artisunate. Artemisinin was heated with the alkali at 100°C for 10 minutes 
which resulted in discolouration. The coloured compound has not yet been 
identified but it is apparent that subjecting artemisinin to an alkaline material 
at high temperatures may be responsible for this discolouration. 
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Figure 4.12 Calibration curve of artemisinin 
 
A calibration curve was obtained using standard solutions of artemisinin (5, 
10. 15, 20, 25 and 30 µg/mL) as shown in figure 4.12. This calibration curve 
was used to calculate the artemisinin content from the produced extrudates. 
4.2.2. Preparation of solid dispersion 
From the rheology experiments, non-linear data was obtained from the 50% 
artemisinin loaded sample, therefore a 1:1 (w/w) artemisinin: Soluplus® ratio 
was selected. DSC and rotational rheology can serve as simple techniques 
for selecting temperature profiles and extrusion was carried out at T110. The 
temperature profile of T110 was considered as the optimum setting, 
exhibiting moderate levels of torque and suitable extrudate consistency. 
Three extrusion batches were carried out:  ArtSD1, ArtSD2 and ArtSD3. 
Details of these batches are summarised in Table 4.3.  
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Table 4.3 Summary of extruded materials 
 
Batches 
Screw 
configuration 
(shown in 
Table 3.3) 
Proportion Temperature 
Profiles 
(shown in 
Table 3.4) 
Visual  
Observation 
Drug Polymer Citric 
acid 
ArtSD1 A 
(Half screw 
length) 
1 1 - T110A 
 
ArtSD2 B 
(Full screw 
length) 
1 1 - T110B 
 
ArtSD3 B 
(Full screw 
length)  
1 0.95 0.05 T110 
 
4.2.3. Characterisation of extrudates 
4.2.3.1. Assay 
From a visual observation, it was found that ArtSD2 was darker in colour 
when compared to ArtSD1. However, the assay of the product was in the 
range of 80 to 85% and 75 to 80% for ArtSD1and ArtSD2 respectively. 
Therefore, the physical mixture (1:1) containing 5 % citric acid was extruded 
and the assay of the modified formulation ArtSD3 was found to be 103%.  
Assay results are shown in Table 4.4. As ArtSD3 showed a higher drug 
content, this formulation was used for further characterisation.  
Table 4.4 Assay results of extrudates 
Batches Average Purity (%) Standard deviation 
ArtSD1 83.30 1.85 
ArtSD2 78.65 2.79 
ArtSD3 103.20 3.54 
Extruded artemisinin 99.33 0.57 
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crystals (neat) 
Extruded Soluplus® 
(neat) 
- - 
4.2.3.2. Differential Scanning Calorimetry 
The thermogram of ArtSD3 (figure 4.13) showed an exotherm at 180°C, 
representing the liberation of formic acid; however the material did not exhibit 
a melting endotherm corresponding to that of artemisinin, indicating that an 
amorphous state of the solid dispersion had been achieved.  
 
Figure 4.13 DSC curve for ArtSD3. 
4.2.3.3. Powder X-ray diffraction 
The effect of the processing parameters on the materials’ physical properties 
was examined by comparing the X-ray diffraction patterns of ArtSD3 with 
artemisinin, Soluplus® and physical mixtures as shown in figure 4.14. 
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Figure 4.14 Experimental PXRD patterns of pure artemisinin, physical mixture 
and ArtSD3 
 
Artemisinin exhibited characteristic peaks at 2θ of 7.5, 12, 14.5, 20.2 and 
21.9 degrees, while Soluplus®, being amorphous in nature, did not show any 
crystalline peaks. For the physical mixture, the crystalline peaks of 
artemisinin were clearly observed. The complete disappearance of crystalline 
peaks in ArtSD3 ilustrated that the prepared solid dispersion using Soluplus® 
was transformed into an amorphous state. The intensity of the crystalline 
peaks was low for the physical mixture when compared to those for pure 
artemisinin. This signifies that the presence of Soluplus® had no influence on 
the physical state of artemisinin. 
4.2.3.4. In-vitro dissolution study 
The pharmaceutical performance of the extrudates was investigated by in-
vitro dissolution tests and compared with the pure drug and physical mixture, 
as shown in figure 4.15.  
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Figure 4.15 Drug release rates from pure drug, physical mixture of drug and 
polymer and ArtSD3 
 
The dissolution profile of ArtSD3 was approximately five times higher 
compared to that of the pure drug. The dissolution rate of the physical 
mixture was greater than that of pure artemisinin, although not considerably. 
In the first 45 minutes, 92% of the drug was released from ArtSD3 which is 
presumably due to transferring the crystalline state to the amorphous state 
resulting in a higher dissolution rate. In 60 minutes, 75% drug release was 
achieved from the solid dispersions of artemisinin with PVP (1:5 ratio), 
prepared by supercritical fluid technology (Nijlen et al., 2003). Niijlen et al. 
prepared solid dispersions of artemisinin in a polyvinylpyrrolidone(PVP) K25 
polymer carrier using a solvent evaporation method. This experiment was 
performed in dichloromethane and the solvent was removed by rapid 
evaporation at 45°C under low pressure. As a solvent based technique, this 
batch process was complicated to scale up. Therefore, Soluplus® can be 
said to be equally effective in improving the dissolution rate of artemisinin.  
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4.2.3.5. Pharmacokinetic study 
To validate the in-vitro results, in-vivo experiments were performed. The 
bioavailability of pure artemisinin and ArtSD3 were studied in Albino rats.This 
was done to verify the correlation between the in-vivo data and the data 
obtained by the in vitro dissolution method.  
 
Figure 4.16 Artemisinin calibration curve in plasma 
 
A calibration curve was obtained using standard solutions of artemisinin in 
plasma (5, 10, 20, 40, 60, 80, 100, 120, 140 and 160 µg/ml). Figure 4.16 
shows the calibration curve, the equation for the best-fit line and regression 
coefficient value. This calibration curve was used to calculate the amount of 
artemisinin present in plasma.  
Twelve rats were used for each formulation and samples were analysed 
once. The plasma concentration against time curve was obtained after the 
oral administration of the formulations. The plasma concentrations for pure 
artemisinin and ArtSD3 are displayed in Table 4.5 and 4.6 respectively. The 
plasma concentration of artemisinin and ArtSD3 were 18.33 µg/ml and 42.59 
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µg/ml. The plasma concentration of ArtSD3 clearly shows the enhanced 
bioavailability of ArtSD3 compared to that of the pure drug.  
The maximum artemisinin concentration in the plasma reached by ArtSD3 
demonstrated a better release in the amorphous state (shown in figure 4.17). 
A typical chromatogram of a rat plasma sample spiked with 120 µg/ml 
artemisinin, with a retention time of (RT) 9.96 and an internal standard 
artemether RT of 16.68 is shown in Figure 4.18.  The areas under the curves 
for both pure artemisinin and ArtSD3 are shown in table 4.7.  
 
Figure 4.17 Plasma concentration after oral administrating pure artemisinin 
and ArtSD3 
 
 
Figure 4.18 A typical chromatogram of a rat plasma sample spiked with 120 
µg/mlartemisinin RT 9.96 and internal standard artemether RT 16.68 
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Artemisinin is a Biopharmaceutical classification system (BCS) class II drug 
meaning that it has low solubility and high permeability. It has been reported 
that artemisinin has only 8-10% bioavailability (Balint et al., 2001), a short 
half-life and a high first pass metabolism. These properties contribute to 
partial parasite removal, resulting in artemisinin recrudescences (Titulaer et 
al., 1991). 
Table 4.5 Plasma concentration of pure artemisinin 
  Plasma Concentration of pure artemisinin(µg/ml) 
Time(h) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Mean 
0 0 0 0 0 0 0 0 
0.5 7.78 6.67 7.78 7.78 8.89 6.67 7.59 
1 15.56 8.89 10 11.11 12.22 17.78 12.59 
2 31.11 8.89 10 11.11 12.22 17.78 15.18 
4 18.89 17.78 20 18.89 17.78 16.67 18.33 
6 16.67 12.22 10 8.89 7.78 7.78 10.55 
8 10 7.78 7.78 6.67 6.67 6.67 7.59 
24 8.89 10 8.89 6.67 7.78 8.89 8.51 
 
Table 4.6 Plasma concentration of ArtSD3 
Plasma Concentration of ArtSD3 (µg/ml) 
Time(h) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Mean 
0 0 0 0 0 0 0 0 
0.5 22.22 24.44 21.11 22.22 23.33 20.00 22.22 
1 27.78 26.67 26.67 26.67 28.89 27.78 27.41 
2 33.33 31.11 28.89 34.44 32.22 35.56 32.59 
4 43.33 41.11 45.56 41.11 42.22 42.22 42.59 
6 26.67 33.33 35.56 32.22 33.33 35.56 32.78 
8 20.00 23.33 28.89 27.78 30.00 31.11 26.85 
24 13.33 18.89 20.00 18.89 20.00 17.78 18.15 
 
Jinadasa et al. have observed that the absorption of artemisinin is poor and 
negligible when it reaches the lower gastrointestinal (GI) tract; specifically the 
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colon (Jinadasa et al., 1996). Thus, enhancing the solubility of artemisinin 
could ensure better drug dissolution in the upper GI tract, greater 
bioavailability and in turn, reduced chances of recrudescence. A rapid 
dissolution rate and hence absorption could lead to enzyme saturation during 
the first pass in the liver, resulting in a higher fraction of unmetabolised drug 
entering the systemic circulation, compared to a slower rate of drug 
dissolution. Many attempts have been made to improve the dissolution rate 
of artemisinin but ultimately these have not been successful due to process 
complexity and cost constraints. Though cyclodextrin complexation resulted 
in a threefold improvement in solubility which doubled the bioavailability 
(Titulaer et al., 1991), the proposed formulation was ‘bulky’ because a 1:1 
molar ratio was used. 
Table 4.7 Area under curves for pure artemisinin and ArtSD3 
Rats Pure artemisinin 
(µg.hr/ml) 
ArtSD3  
(µg.hr/ml) 
Rat 1 47.01 127.15 
Rat 2 58.33 147.22 
Rat 3 37.77 164.03 
Rat 4 32.56 157.64 
Rat 5 34.65 165.49 
Rat 6 55.83 165.49 
 
ArtSD3 showed a three-fold increase in AUC compared to pure artemisinin. 
The average Cmax concentration (maximum plasma concentration) for 
artemisinin and the ArtSD3 were 16µg/ml and 40µg/ml respectively, whereas 
Tmax (Time to reach Cmax) was 4 hours for both.  
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4.2.3.6. Stability study 
Although an interest in solid dispersions is growing rapidly, the 
commercialisation of solid dispersions in the pharmaceutical industry is 
limited. In three decades, only two solid dispersion formulations have been 
marketed: griseofulvin with polyethylene glycol and nabilon with 
polyvinylpyrrolidone (Serajuddin et al., 1999). The formulation stability is a 
major issue for solid dispersions owing to phase separation. There are also 
chances of crystallisation occurring during storage as the drug is molecularly 
dispersed (Ford et al., 1986). Shibata et al. proposed that moisture might 
affect the physical stability of solid dispersions due to the crystallisation of 
the amorphous drug (Shibata et al., 2013). In addition, some carriers can 
exist in thermodynamically unstable states in solid dispersion forms and 
hence suffer from stability problems (Serajuddin et al., 1999). 
The obtained solid dispersion (ArtSD3) was stored at room temperature and 
a stability study was performed at various intervals immediately after 
extrusion: 1 day, 1 week, 1 month, 3 months, 6 months, 9 months, 12 
months and 24 months by DSC, PXRD and in-vitro dissolution. The DSC 
thermograms, PXRD patterns and in-vitro dissolution profiles of the 
respective extrudates were similar to the original data. The PXRD patterns of 
ArtSD3 at 1 month, 3 months, 6 months, 9 months, 12 months and 24 
months are shown in figure 4.19. There was no variation in the result due to 
time, which proves that the stability of the HME prepared artemisinin: 
Soluplus® solid dispersions. 
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Figure 4.19 PXRD patterns of ArtSD3 at different time intervals 
4.2.4. Summary of chapter 
It is clear that the processing of thermolabile drugs is one of the most 
challenging and convoluted aspects of HME. Intensive shear and high 
temperatures are potential drawbacks of HME, but the introduction of twin 
screw extruders allows different screw designs for various pharmaceutical 
applications and the availability of wide range of polymers can help to 
overcome the problem. Polymer selection and screw geometry have been 
considered as the primary parameters for the extrusion experiments carried 
out. The compatibility of artemisinin and Soluplus® was initially studied using 
rotational rheology. These primary studies formed the background set 
conditions for the processing of artemisinin. However, the batch processed 
using a half length screw (ArtSD1), exhibited only 87% drug content and it 
was difficult to quantify the degradation in the ArtSD1 and ArtSD2. Citric acid 
was found to suppress the degradation of the drug at the processing 
temperature by maintaining a neutral microenvironment.  
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The release rates of the drug were significantly improved compared to the 
pure drug and the physical mixture or drug and polymer, in both in-vitro and 
in-vivo studies. The system was shown to be stable up to at least 24 months, 
highlighting the potential for the enhancement in delivery of this important but 
difficult API. 
This work has demonstrated that the extrusion of a thermolabile drug, with 
the amphiphilic polymer Soluplus® and a small amount of citric acid, can 
lead to a stable and soluble solid dispersion.  
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5. Polymorphic transformation using high temperature 
extrusion 
This chapter reports a novel solvent free method to generate and stabilise 
metastable forms of APIs. The stability of the metastable form obtained by 
high temperature extrusion is greater than that of polymorph prepared using 
a solvent based technique. A schematic presentation of the chapter is shown 
in figure 5.1.  
Figure 5.1 A schematic presentation of the chapter 
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5.1. Introduction  
There is a drive within the pharmaceutical industry to explore the use of 
metastable polymorphs of drugs whose most stable form has low solubility, 
low bioavailability, intellectual property (IP) issues, manufacturing difficulties 
or chemical instability (Hilfiker et al., 2006). However, it is known that in 
solution, although the less stable forms nucleate first due to a higher 
nucleation rate, they transform through any available pathways to more 
energetically stable forms (Davey et al., 1997; Schroer et al., 2003 and 
Zhang et al., 2004). The presence of solvent often enables such 
transformations and consequently, it may be difficult to isolate the metastable 
polymorph before it undergoes solvent mediated transformation. Various 
attempts have been made to disrupt the growth of the stable form using 
additives (Gu et al., 2002) or structurally similar substrates (Mitchell et al., 
2001). Such methods raise additional issues as they are inherently time 
consuming, expensive and restricted to small scale screening applications.   
Seeding a solution is a well known approach to crystallise a metastable form 
(Beckmann et al., 2000). Even so, some associated concerns must be 
considered such as the selection of a reliable method for generating seed 
crystals, the temperature range of the metastable zone for harvesting, and 
the requirement for thorough drying (Deegan et al., 1997). Another approach 
is contact line crystallisation, which Capes et al., employed to produce the 
metastable polymorph of paracetamol (Form II) (Capes et al., 2007). 
Although Form II had been previously grown by several routes, the method 
of Capes et al. generated crystals of Form II which remained stable and did 
not revert to the most stable polymorph, Form I. In this method, 
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crystallisation takes place on the receding miniscus of an evaporating 
solution. The conditions reduce the possibility of solvent mediated 
transformation since the crystals are continually removed from solution and 
the amount of solvent is lowered by evaporation. These findings suggest that 
metastable forms may be produced in a solvent free environment, since 
kinetic pathways to the stable form are unavailable.  This potentially useful 
method of forming metastable crystals is however, difficult to scale up.    
Here, application of high temperature extrusion (HTE) was explored to 
produce solvent-free metastable drug forms. Though the HTE technique is 
similar to hot melt extrusion, it operates below the melting point of the API. 
This is the first application of such a method to the control of polymorphic 
transformation. Different APIs such as artemisinin, piracetam, 
carbamazepine, chlorpropamide, paracetamol and theophylline were 
processed using this method. From these, successful polymorphic 
transformation was achieved in artemisinin, piracetam, chlorpropamide and 
carbamazepine. The major focus of the work presented in this chapter is the 
polymorphic transformation of artemisinin; however transformations of a 
wider range of APIs have also been included as part of the investigation of 
the HTE process. 
Artemisinin exhibits two polymorphic forms; orthorhombic and triclinic, as 
shown in figure 5.2. The commercially available orthorhombic form is 
considered to be thermodynamically more stable and has lower water 
solubility whilst the metastable triclinic form has a higher dissolution rate and 
has a tendency to undergo solvent mediated transformation (Chan et al., 
1997).  
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The HTE process has been used to produce crystals of the triclinic form of 
artemisinin which remained stable for over two years, by applying a 
combination of controlled temperature and shear. Attempts have also been 
made to understand the mechanisms causing this transformation.  
 
 
                                                                                                                                                           
Figure 5.2 A shows the molecular structure of artemisinin, B the orthorhombic 
form of artemisinin (space group P212121) and C the triclinic form (space 
group P1). 
Crystal data for artemisinin 
Orthorhombic: P212121/n, a = 24.08Å, b = 9.44Å, c = 6.36Å and R- factor = 0.075 
Triclinic: P1/n, a = 9.89 Å, b = 15.34 Å, c = 9.88 Å, α = 90.92, β = 102.99, γ = 
93.24 and R factor = 0.052 
5.2. Result and discussion  
As reported in the previous chapter, the stability of artemisinin at high 
temperature and shear was a potential issue during HME and as such was 
the subject of further investigation. Whilst addressing this discolouration 
issue in solid dispersions, extrusion of artemisinin crystals and physical 
mixtures were performed at 130ºC.  It was observed that one of the extruded 
materials showed an additional PXRD peak at 2θ:7.89 (displayed in figure 
5.3) which was found to be a characteristic peak of the triclinic form of 
A 
B 
C 
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artemisinin. This surprising observation acted as a seed for further 
investigations and the subsequent development of HTE for polymorphic 
transformations.  
 
Figure 5.3 Experimental PXRD patterns of extruded artemisinin and Soluplus® 
at 130º C. Red arrow indicates the characteristic peak of the triclinic form of 
artemisinin 2θ: 7.89 
 
5.2.1. Preliminary screening  
Preliminary screening was performed using hot stage microscopy and a 
model shear cell. 
5.2.1.1. Hot Stage Microscopy  
Isothermal hot stage microscopy experiments were performed to determine 
whether thermal treatment alone was able to cause complete polymorphic 
transformation of artemisinin crystals. Orthorhombic crystals of artemisinin 
were subjected to isothermal heating at 140°C on a hot stage for 90 min and 
changes in form were recorded. Images were collected periodically and the 
product at the end of the experiment was collected and characterised by 
PXRD (shown in figure 5.4). PXRD results for the orthorhombic and triclinic 
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polymorphs indicated the ratio of the peak intensities at 2θ=9.95 and 7.80 
respectively can be used to estimate the fraction of triclinic polymorph 
present. The PXRD pattern of the product showed a small peak at 2θ=9.95; 
characteristic of the triclinic form dominated by the orthorhombic peaks. 
The orthorhombic to triclinic phase transformation was observed to occur 
slowly on a hot stage when isothermal conditions were maintained at 140°C. 
Fine orthorhombic crystals were seen to disappear gradually while thicker, 
plate-shaped crystals started to appear during polymorphic transformation. 
After a longer period at 140°C the orthorhombic crystals underwent 
sublimation. Recorded images are shown in figure 5.5 (a), (b) and (c). During 
this process of transformation an intermediate vapour phase was observed 
as the triclinic plates were growing at the expense of contracting 
orthorhombic fine crystals. Similar vapour phase polymorphic transformation 
has been observed in the case of venlafaxine hydrochloride (Roy et al., 
2007). The intensity of the thick, plate-like crystals increased and there was a 
partial transformation into the triclinic form. Complete polymorphic 
transformation was not achieved at high temperature; in fact many 
pharmaceutical materials subjected to higher temperatures over a long 
period of time are likely to suffer degradation.  
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Figure 5.4 Experimental PXRD patterns of thermally treated material at 
different intervals 
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Figure 5.5 Microscopy images during isothermal heating of orthorhombic 
crystals at 140°C (A) 0 min, (B) 45 min and (C) 90 min; during isothermal 
heating of orthorhombic crystals at 140°C and with 0.5 s-1 shear rate (D) 0 min, 
(E) 8 min and (F) 15 min.    
 
In order to confirm that polymorphic transformation was taking place through 
vapor phase sublimation, experiments were carried out using a sublimation 
unit. Orthorhombic crystals were heated at 145°C. After 90 minutes a new 
crystal phase started growing on the condensing surface (shown in figure 
5.6). The PXRD patterns confirmed that the collected sublimed crystals were 
the triclinic form. The PXRD pattern of the powder collected from the lower 
vessel showed partial transformation to the triclinic form (figure 5.7).   
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Figure 5.6 Polymorphic transformation of artemisinin crystals by sublimation   
 
Figure 5.7 Experimental PXRD patterns of orthorhombic form, sublimed 
crystals and crystals collected from lower vessel  
Therefore, a combination of shear and temperature was applied in order to 
achieve complete polymorphic transformation. 
5.2.1.2. Shear Cell 
 
The next experiment was performed to investigate the effect of temperature 
and shear using a shear cell. Initial results indicated that transformation was 
not complete when artemisinin was exposed to high temperature alone. The 
shear cell provided an opportunity to study material state under model shear 
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conditions and has been widely used in polymer research to study flow and 
shear enhanced crystallisation. The structural dynamics of complex fluids 
can be directly monitored via a standard optical microscope while subject to 
precisely controlled temperature and various shear modes. Shear cell 
microscopy was performed using a Linkam shear cell (CSS450) coupled with 
a polarised light microscope connected to a video capture system. The 
orthorhombic form of artemisinin was loaded between the top and bottom of 
highly polished quartz windows of the shear cell and the gap between the 
two plates was reduced to 30µm by slowly lowering the upper glass plate of 
the Linkam device. The sample was isothermally heated at 140° C for 15 min 
and a steady shear rate of 0.5 s-1 maintained. Treated samples were 
collected periodically and analysed by PXRD (shown in figure 5.8). 
Interestingly, complete transformation to the triclinic form was observed after 
only 13 minutes. The captured images are shown in figure 5.5 (d), (e) and (f). 
No polymorphic transformation was observed at lower shear rates. It was not  
possible to track individual crystals of artemisinin since during continuous 
shear the breakdown of crystals and vapour phase transformation occurred 
simultaneously. In this process the applied mechanical shear stress 
continually disrupts the crystalline structure which leads to the formation of 
new surfaces being continuously exposed to high temperatures. The process 
of transformation is therefore accelerated under high temperature and shear.  
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Figure 5.8 Experimental PXRD patterns of the material treated in shear cell 
5.2.2. High temperature extrusion of artemisinin  
For high temperature extrusion, temperatures of 120 and 140°C were 
selected to avoid melting or degradation because of any rise in temperature 
in the extrusion process due to viscous shearing. The product of a series of 
extrusion experiments were analysed using PXRD. Results are summarised 
in figure 5.9 which shows that the temperature profile T140, screw rotation 
speed of 20 rpm and a high shear intensity screw configuration caused 
almost total conversion to the triclinic form.  The residence time during 
extrusion was generally 10 – 15 minutes depending on the screw geometry 
and set screw rotation speed. Generally speaking both higher shear intensity 
and higher set temperature resulted in improved conversion levels. Precise 
levels of shear intensity provided by HTE could not be quantified, although 
different intensities were achieved by modification of extruder screw 
geometry. 
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Figure 5.9 Effect of temperature and shear on residual polymorph 
 
5.2.3. Characterisation of the extruded products 
5.2.3.1. Powder X-ray diffraction  
The generation of a triclinic polymorph was confirmed by PXRD analysis. 
The PXRD pattern of orthorhombic form exhibited peaks at 2θ: 9.45, 2 θ:  
18.5, 20: 14.95 and 20: 15.09 whereas the triclinic form exhibited peaks at 
2θ:7.89, 20: 12.1 and 20: 15.34. These PXRD patterns were confirmed from 
the Cambridge Crystallographic Database as corresponding to orthorhombic 
and triclinic form respectively (shown in figure 5.10).  
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Figure 5.10 Experimental and calculated PXRD patterns of orthorhombic and 
triclinic polymorphs of artemisinin  
5.2.3.2. Differential scanning calorimetry 
 
DSC analysis of the orthorhombic form of artemisinin showed two melting 
endotherms sharp peak at 154.81°C while the processed artemisinin showed 
only one melting endotherm at 154.75°C corresponding to the triclinic form 
(displayed in figure 5.11).  
 
Figure 5.11 DSC curves of triclinic and orthorhombic artemisinin 
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The enthalpy for melting of the triclinic form was 82.85 J g-1 and for the 
orthorhombic form 82.91 J g-1. The thermal data did not provide any 
information about stability of two polymorphs.  
5.2.3.3. Fourier Transform Infrared Spectroscopy 
 
FTIR spectra for both unprocessed and processed artemisinin were similar 
(shown in figure 5.12). The spectra for triclinic crystals were broader than the 
orthorhombic crystals in the range between 2845 to 3000 cm-1 and 1300 to 
1500 cm-1. This observation is also similar with a report by Chan et al. (Chan 
et al., 1997). 
 
Figure 5.12 FTIR spectra of the orthorhombic and triclinic forms of artemisinin 
5.2.3.4. High performance liquid chromatography: Mass Spectrometry  
The HPLC method using a UV detector was described in an artemisinin 
monograph without any derivatisation but has limited sensitivity. HPLC-MS is 
a sensitive technique which is capable of detecting impurities which were not 
observed in HPLC-UV method. The use of mass spectroscopy permitted an 
accurate detection of molecular formula. For orthorhombic artemisinin, the 
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chromatogram showed a high resolution of mass spectrum at 283.2 ion 
corresponding to the molecular formula C15H23O5. Additional peaks were 
obtained at 324.4, 265.1, 237.1 and 300.3 related to [M+Na], loss of water, 
loss of water and CO and loss of water and two CO respectively (Stringham 
et al., 2009). The mass spectra obtained for the triclinic form was identical to 
the orthorhombic form. The retention time for the orthorhombic form was the 
same as the retention time of the triclinic form i.e. 8.23 and 8.24 minutes 
respectively with a well-shaped peak, this result demonstrated the purity of 
extruded artemisinin (displayed in figure 5.13). Lin et al. has reported that 
artemisinin degrades when exposed to temperatures of 150°C for 
approximately 15 minutes and this thermally decomposed artemisinin shows 
numerous additional peaks of C14H21O3  ion. In this decomposed product, the 
spectrum at 283.2 disappears and shows a largest peak at 237.15 but 
artemisinin shows both spectra. It is also stated that retention time shifts from 
6.5 to 7.3 minutes for thermally degraded artemisinin (Lin et al., 1985). 
These two observations are indicative of the formation of 100% triclinic 
artemisinin without any degradation.   
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Figure 5.13 LCMS spectrum for orthorhombic and triclinic artemisinin 
5.2.3.5. Density Determination  
True density was measured for artemisinin polymorphs using helium 
pycnometry in triplicate and an average was calculated. True density for the 
orthorhombic and the triclinic forms were found to be 1.298 gm/ml and 1.286 
gm/ml respectively. These values were similar to the densities reported by 
Chan et al (Chan et al., 1997) as summarised in Table 5.1. The measured 
true density correlates with Burger and Ramberger who stated that a solid 
form with higher density will be more stable at 0 K, compared to the solid 
form with the lower density (Burger et al., 1979).     
Table 5.1 Densities of artemisinin polymorphs  
Forms True Density (gm/ml) 
(Measured) 
True Density (gm/ml) 
(Reported) 
Orthorhombic 1.298 1.294 
Triclinic 1.286 1.286 
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5.2.4. Stability of the triclinic crystals  
The stability of crystals of the triclinic form produced by extrusion was 
compared to those produced by recrystallisation. Orthorhombic crystals were 
recrystallised from cyclohexane at 80°C and the triclinic crystals were 
obtained by vacuum drying. PXRD was used to monitor transformation to the 
orthorhombic form. It was observed that the triclinic form obtained by the 
solvent method transformed into the orthorhombic form within a week when 
stored at room temperature (PXRD patterns are shown in figure 5.14). To 
obtain further insight, traces of solvent in the crystal were measured by gas 
chromatography. The residual solvent of cyclohexane was found to be 1.25% 
by volume. This suggests that even minor traces of a solvent may be enough 
to cause solvent mediated transformation. In contrast the triclinic form 
obtained from the solvent free extrusion method was found to be stable for 
more than two years.  
 
Figure 5.14 Experimental PXRD patterns of the triclinic form obtained from 
recrystallisation  
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The impact of different solvents; acetone, ethanol, methanol and water on 
the extruded triclinic form were studied. 0.1ml of solvent was mixed with 3g 
of extruded triclinic material. PXRD patterns were recorded every day for a 
month and then once a month for a period of 15 months. PXRD patterns of 
each sample showed rapid transformation to the orthorhombic form, except 
for the sample with water as a solvent (shown in figure 5.15).  
 
Figure 5.15 Transformation of the triclinic to the orthorhombic form in 
presence of different solvents 
 
The solubility of artemisinin in different solvents was measured at 20°C using 
a gravimetric method and after saturation solubility was monitored for 6hrs. 
The experiment was repeated three times and an average was calculated. 
The triclinic form showed slightly higher solubility than the orthorhombic form 
in all solvents except water. In the case of water the triclinic form is five times 
more soluble than the orthorhombic form. In the light of this significant 
difference in solubility, rapid transformation of the triclinic form to the 
orthorhombic may be expected, but surprisingly the triclinic form remained 
stable in the presence of water.  This may be due to the low solubility of both 
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forms in water and generally speaking the transformation rate appeared to 
correlate well with the solubility of the triclinic form in the solvent (Table 5.2). 
Table 5.2 Solubility of art in different solvents and transformation duration 
 
 
 
 
 
 
 
 
 
5.2.5. Computational studies 
To understand stability and solvent mediated transformation of artemisinin 
polymorphs, a computational analysis using the Morphology and Sorption 
modules of Material Studio Software 4.1.0 (Accelrys, 2006)
 
was performed.   
 5.2.5.1. Geometry Optimisation  
The 3D crystal structures of both polymorphs were obtained from the 
Cambridge Structural Database (CSD) with codes QNGHSU (orthorhombic) 
and QNGHSU01 (triclinic). Geometry optimisation was performed using 
Universal, CVFF, PCFF and Dreiding force fields with built in and 
equilibrated charges (QeQ) and the calculated values were compared with 
the experimental values. The force field results are shown in Table 5.3. The 
PCFF force field (Hill et al., 1995) with QEq charges (Rap et al., 1991) was 
found to calculate lattice parameters in closest agreement with experimental 
data and therefore this force field was used in all further calculations.  A 
further check on the quality of the force field was performed by comparing 
Solvent Solubility 
orthorhombic 
(mmol/L) 
Solubility 
triclinic  
(mmol/L) 
Transformation 
duration 
Acetone 850.06 927.99 Immediate  
Ethanol 92.10 113.34 3 days  
Methanol 138.13 159.39 3 days  
Water 0.22 1.11 No transformation 
observed in15 
months  
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the energy difference between the calculated lattice energies of the two 
geometry optimised crystals.  The PCFF force field with QEq charges 
predicted the orthorhombic form to be more stable than the triclinic form by 
0.14kcal/mol. This compares well with 0.06 kcal/mol found from the 
enthalpies of the melting transitions from DSC measurements.  It was noted 
however that the calculated energies take no account of temperature. The 
agreement between the calculated and experimental geometries and 
energies gives some confidence in the calculations of crystal habit reported 
below, although it must be emphasised that such calculations are only 
indicative of the likely significant surfaces to be found in these crystals. 
Table 5.3 Geometry optimisation calculation for orthorhombic and triclinic 
forms of artemisinin  
Force fields Orthorhombic Triclinic Average 
error (%) 
 a b c a b c α β γ  
Experimental 24.0 9.4 6.4 9.9 15.3 9.9 90.9 103.9 93.2  
Dreiding + QeQ 24.2 9.5 6.5 9.8 16.2 10.0 89.8 102.0 90.0  
Mean error 0.8 1.0 2.9 -0.6 5.7 1.5 -1.2 -0.9 -3.2 2.5 
Universal + 
QeQ 
24.1 9.1 6.4 9.7 15.1 9.9 90.3 103.2 96.9  
Mean error 0.2 -
3.3 
0.8 -1.2 -1.3 0.9 -0.7 0.2 4.0 1.9 
CVFF (Built in 
charge) 
25.8 8.8 6.4 10.0 14.5 10.1 90.0 105.4 90.1  
Mean error 7.3 -
6.0 
1.1 2.1 -4.8 3.0 -1.0 2.4 -3.3 4.0 
PCFF (Built in 
charge) 
25.7 8.8 6.2 9.9 14.7 10.0 89.8 103.6 91.8  
Mean error 6.8 -
5.8 
-1.1 0.9 -4.1 1.4 -1.2 0.7 -1.5 3.4 
CVFF + QeQ  25.0 9.0 6.4 9.7 15.3 9.9 89.9 102.4 97.7  
Mean error 3.9 -
4.6 
0.9 -1.5 0.3 0.6 -1.1 -0.5 4.8 2.7 
PCFF + QeQ 24.1 9.5 6.4 9.6 15.4 9.8 90.3 100.9 90.2  
Mean error 0.1 0.5 1.0 -3.0 0.6 -0.4 -0.7 -2.0 -3.2 1.7 
* The average error is calculated by taking the square root of sum of the 
squared error and dividing by 9.  
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5.2.5.2. Morphology Prediction  
BFDH, Growth and Equilibrium morphologies of both polymorphs were 
calculated using the Morphology modules and results are summarised in 
Table 5.4. The predicted growth and equilibrium morphologies were similar, 
with the {200} and {100} faces dominating the morphologies of the 
orthorhombic and triclinic faces respectively.  
The cohesive strength of crystal planes is related to their attachment 
energies (Wildfong et al., 2007). Therefore, growth morphologies of the 
polymorph were calculated using the Morphology module, during which 
attachment energies of all low index faces were calculated. The calculated 
crystal habit was dominated by, the {200} faces for the orthorhombic form 
and {100} for the triclinic form with percentage areas of 58.3% and 55.4% 
respectively (Table 2). The molecular arrangement at the possible slip planes 
of the orthorhombic and triclinic forms are shown in figure 5.16. It clearly 
shows the molecular density is higher on the (100) surface of the triclinic 
form compared to the (200) surface of the orthorhombic crystal. In contrast 
the slip plane surfaces of chlropropamide demonstrated significant similarity 
in the molecular arrangement at the slip plane of two polymorphs which was 
considered to be responsible for interconversion of these polymorphs 
(Wildfong et al., 2007). The difference in molecular arrangements of surfaces 
may have been responsible for transformation of orthorhombic to triclinic 
rather than interconversion under applied shear.   
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                                 a                                          b 
Figure 5.16 Orthorhombic and triclinic crystal structures, viewed in the (a) 
(200) plane and (b)  (100) plane respectively 
Equilibrium morphology was used for further computational analysis because 
it the surface energy of each surface. After analysing the surface area of the 
predicted morphology it was found that the {200} faces for the orthorhombic 
form and the {100} faces for triclinic form, with percentage areas of 88% and 
37% respectively had the maximum surface area as shown in figure 5.17.  
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Table 5.4 Results of morphology calculations using different methods 
Orthorhombic Triclinic 
BFDH 
hkl Total facet area 
(%) 
hkl Total facet area 
(%) 
200 36.6 010 21.9 
110 37.8 001 11.2 
101 23.4 100 10.6 
Growth Morphology 
hkl Total facet area 
(%) 
hkl Total facet area 
(%) 
200 29.2 100 27.7 
110 23.7 001 10.9 
101 10.0   
Equilibrium morphology 
hkl Total facet area 
(%) 
hkl Total facet area 
(%) 
200 44.1 100 18.8 
 
The molecular arrangement of these two faces will have significant influence 
on the properties of the crystal. The oxygen atoms of the orthorhombic 
polymorph are exposed in the channels of the {200} surface resulting in a 
more hydrophilic surface than the triclinic form (shown in figure 5.13).  
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E   
 
                                  
                                                           F   
Figure 5.17 Predicted habit of the orthorhombic form (A) and its (200) surface, 
top view (B) and side view (C).  Predicted habit of the triclinic crystal form (D) 
and its (100) surface, top view (E) and side view (F) 
5.2.5.3. Sorption Studies 
To investigate the effect of solvents such as acetone ethanol, methanol and 
water on the surface of the crystals, the sorption module was used to 
calculate adsorption energy. The sorption module simulates a pure 
adsorbate in a sorbent framework by using the Metropolis Monte Carlo 
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method. The calculated adsorption energy for different solvents on the {100} 
surface of the triclinic form and the {200} surface of the orthorhombic form 
are shown in Table 5.5. The adsorption energies are larger on the 
orthorhombic {200} surface, which may be due to adsorption into a channel 
which will provide a large contribution from van der Waals interactions.  This 
is supported by the fact that the strength of adsorption on the {200} surface is 
proportional to the size of the molecule.  Adsorption on the triclinic {100} 
surface shows little differentiation between the four solvents studied and 
these results are not able to explain the difference in stabilities of the triclinic 
crystals in acetone (which rapidly convert to the orthorhombic form) and in 
water (which are stable for more the 15 months).  As mentioned previously, 
the reason for the stability of the triclinic crystals is most likely to be due to 
their low solubility. The aqueous solubility of the triclinic form is only 0.312 
mg/ml.  
Table 5.5 Adsorption energies of solvents on the orthorhombic (200) and 
triclinic (100) surfaces of artemisinin 
 
 
 
 
 
 
Solvents Adsorption energy 
for the 
orthorhombic 
(200) surface 
(kcal/mol) 
Adsorption energy for the 
triclinic (100) surface 
(kcal/mol) 
Acetone -16.30 -7.10 
Ethanol -15.75 -6.27 
Methanol -14.27 -5.68 
Water -11.76 -5.97 
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5.2.6. Mechanism of polymorphic transformation during HTE 
Pharmaceutical processing has the potential to disrupt the crystal lattice of 
APIs and has thus gained considerable attention (Gerhardt et al., 1994 and 
Phadnis et al., 1997). Different molecular arrangements can provide diverse 
physical and chemical properties in pharmaceutical substances thus altering 
solubility, density, stability and bioavailability (Modi et al., 2013). Several unit 
operations employed to prepare solid dosage forms, such as grinding, 
milling, drying and compression may induce solid state polymorphic 
transformation (Morris et al., 2001). Some elegant examples which utilise 
such process induced transformation have been described in pharmaceutical 
research.  Tablet compression has been reported to cause a polymorphic 
transition in drugs, such as acetaminophen, piroxicam, carbamazepine, 
phenylbutazone and chlorpropamide, which alters the physicochemical 
properties of these drugs and finally influences the dissolution rate and 
bioavailability of the final products (Lin, 2007). Grinding can also induce 
polymorphic transitions in caffeine, theophylline and famotidine (Cheng et al., 
2008). Recently some solvent free technologies have been investigated 
which cause complete polymorphic transformations. Trask et al. 
demonstrated the application of solvent assisted grinding to achieve 
polymorphic transformation in anthranillic acid and succinic acid (Trask et al., 
2007).  
The two primary factors responsible for causing this transformation in HTE 
are temperature and shear. Polymorphic transformations induced by high 
temperature or pressure are well known. Louer et al. generated metastable 
piracetam polymorph at room temperature. Form I of piracetam was formed 
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by heating form III to 410K at ambient pressure for 30 min in a glass capillary 
followed by quenching to room temperature (Louer et al., 1995). Boldyreva et 
al. demonstrated pressure induced transformation of paracetamol. The study 
was carried out in a diamond anvil cell and there was no change in a single 
monoclinic form crystal until the pressure was increased up to 4.5 GPa 
(Boldyreva et al., 2002). Sometimes the transformation was observed when 
the pressure was slowly decreased after an initial increase. This 
transformation is dependent on the API and the procedure of 
increasing/decreasing pressure. Cheng et al. discussed the role of 
mechanical stress and rise in temperature during processing in polymorphic 
transformation using a grinding method (Cheng et al., 2007). 
5.2.6.1. Polymorphic Transformation in HTE 
Here, the concept of providing a combination of controlled temperature and 
shear was explored through the application of HTE to induce polymorphic 
transformation. The commercially available orthorhombic form of artemisinin 
was processed in a twin screw extruder. To examine the transformation 
mechanism further, artemisinin from different zones along the extruder barrel 
was collected and characterised by SEM and PXRD. Results are shown in 
Table 5.6 and Figure 5.18. Observation of the collected samples revealed 
that agglomerated material occurred in the later section of the process. 
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Table 5.6 SEM images of the samples collected from different zones of 
extrusion and schematic presentation of the predicted mechanism.   
 
Within the extruder barrel, material passes through three phases; preheating 
which occurs when the material passes through initial conveying zones and 
its temperature is raised to 100°C. During this phase no significant decrease 
in particle size or change in crystal form was observed. In the next zone, 
mixing paddles in the extruder screws were set up to impart high shear and 
the set temperature was raised to 140°C. Also in this region, forward 
conveying of the material is slowed by the mixing elements so the residence 
time is increased. It is assumed that artemisinin in this region of the extruder 
undergoes vapour phase transformation and a significant reduction in size 
due to the high shearing stresses imparted by the screws. Samples taken 
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from this zone did not show complete transformation to the triclinic form, 
although a considerable portion of orthorhombic API had been converted. 
Complete transformation was observed in the next zones (6-8) where the 
high shearing configuration caused further densification of the material 
forming slightly larger agglomerates. Agglomerates conveyed into the final 
zone (8-10) were observed to break down into smaller agglomerates which 
may be due to shearing between the screw and barrel wall. This study has 
provided an understanding of polymorphic transformation of artemisinin 
through the vapour phase which occurs in high temperature extrusion and a 
complex process of agglomeration and de-agglomeration. In a previous 
study concerning the formation of co-crystals in extrusion, similar 
observations were made where by co-crystallisation occurred via melt and 
eutectic phase assisted agglomeration induced by high shear stress (Dhumal 
et al., 2010). The suitability of solid state polymorphic transformation by melt 
extrusion is currently being explored for a range of pharmaceutical 
applications.    
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Figure 5.18 Experimental PXRD patterns of the material collected from 
different zones of extruder 
5.2.7. Performance evaluation  
5.2.7.1. In-vitro dissolution study  
According to Chan, the orthorhombic form of artemisinin has a high density 
and low water solubility compared to the triclinic form (Chan et al., 1997). 
This solubility difference between the orthorhombic form and triclinic form 
was verified by in-vitro dissolution studies. The dissolution test was carried 
out for 10 hours using water as a dissolution medium. The dissolution profile 
of triclinic polymorph was enhanced when compared to the orthorhombic 
form. In 10 hours 25% of artemisinin was released from the orthorhombic 
form while 90% of artemisinin was released from the triclinic form as 
displayed in figure 5.19. This data is in conformation with a work from a 
Malaysian group.  
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Figure 5.19 Dissolution profile of orthorhombic and triclinic artemisinin 
 
5.2.7.2. Pharmacokinetic Study  
To correlate in-vitro dissolution data, a pharmacokinetic study was 
performed. The HPLC calibration curve is shown in Figure 5.20. The 
artemisinin plasma concentrations achieved at different time after 
administration of the orthorhombic and triclinic forms are given in Tables 5.7 
and 5.8 respectively. The plasma concentration-time profiles were plotted 
and Areas Under Curve (AUC) were calculated (shown in Figure 5.21) using 
a Trapezoidal rule. The AUCs obtained for orthorhombic and triclinic forms 
are shown in Table 5.9.   
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Figure 5.20 Calibration curve for artemisinin in plasma samples  
Table 5.7 Plasma concentration of orthorhombic form of artemisinin 
 
Table 5.8 Plasma concentration of triclinic form of artemisinin  
 
 
Plasma Concentration (µg/ml) 
Time(h) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Mean 
0 0 0 0 0 0 0 0 
0.5 14.44 13.33 10 8.89 8.89 6.67 10.37 
1 10 7.78 16.67 14.44 25.56 27.78 17.03 
2 13.33 12.22 20 21.11 15.56 11.11 15.55 
4 22.22 21.11 16.67 15.56 17.78 16.67 18.33 
6 24.44 31.11 27.78 31.11 26.67 28.89 28.33 
8 16.67 11.11 17.78 16.67 18.89 20 16.85 
24 8.89 7.78 8.89 7.78 8.89 6.67 8.14 
y = 0.0095x + 0.018 
R² = 0.9981 
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Concentration (μg/ml)  
Plasma Concentration (µg/ml) 
Time(h) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Mean 
0 0 0 0 0 0 0 0 
0.5 7.78 6.67 7.78 7.78 8.89 6.67 7.59 
1 15.56 8.89 10 11.11 12.22 17.78 12.59 
2 31.11 8.89 10 11.11 12.22 17.78 15.18 
4 18.89 17.78 20 18.89 17.78 16.67 18.33 
6 16.67 12.22 10 8.89 7.78 7.78 10.55 
8 10 7.78 7.78 6.67 6.67 6.67 7.59 
24 8.89 10 8.89 6.67 7.78 8.89 8.51 
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Table 5.9 Comparison of Area Under Curve (AUC) of artemisinin polymorphs 
 
 Orthorhombic (µg.hr/ml) Triclinic (µg.hr/ml) 
Rat 1 188.06 349.17 
Rat 2 233.33 297.50 
Rat 3 151.11 367.5 
Rat 4 130.28 352.5 
Rat 5 138.61 376.94 
Rat 6 223.33 365.28 
Mean 177.45 351.48 
Standard Deviation 44.20 28.34 
 
The triclinic form showed a two fold increase in AUC compared to the 
orthorhombic form. The average Cmax for the orthorhombic form and the 
triclinic forms were 16 µg/ml and 31 µg/ml respectively whereas Tmax were 4 
hrs and 5 hrs for the orthorhombic and the triclinic forms respectively.  
 
Figure 5.21 Plasma concentration profiles of the orthorhombic and the 
triclinic forms of artemisinin 
5.2.3. Summary  
It has been shown that it is possible to manufacture high purity, metastable, 
triclinic crystals of artemisinin using high temperature extrusion. The extruder 
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screw configuration and processing parameters such as temperature and 
screw speed can be optimised in order to produce the desired polymorph 
and level of purity. Shelf-life of the product has been shown to be 
significantly longer than for the triclinic crystals formed by solvent based 
methods, with crystals of the triclinic form still stable after one year. The 
prepared triclinic form also showed an increase in bioavailability. 
5.3. Additional API Case Studies  
High temperature extrusion is a continuous process which can potentially be 
scaled-up to achieve higher throughputs and the method is not limited to 
transformation of artemisinin.  In the following section a range of APIs are 
investigated for use with the HTE technique for solid state phase 
transformation. 
5.3.1. Piracetam 
Piracetam is a noortropic agent recently marketed by UCB Pharma as a 
Nootropil®. It is used to treat age associated mental decline and disorders 
linked with the nervous system. Three polymorphs of piracetam have been 
identified and structurally characterised. Form III is the stable form of 
piracetam. Form I is a metastable form and undergoes solution mediated 
transformation, therefore this drug has been selected as a model drug for 
polymorphic transformation. The molecular structure and physicochemical 
properties of piracetam are displayed in figure 5.22 and Table 5.10 
respectively.  
Chapter 5: Polymorphic transformation using high temperature extrusion  
 
NOVEL FORMULATIONS OF A POORLY SOLUBLE DRUG USING THE EXTRUSION PROCESS
 Page 151 
 
 
Figure 5.22 Molecular Structure of Piracetam 
Table 5.10 Physicochemical properties of piracetam 
Chemical Name 2-(2-Oxopyrrolidin-1-yl)acetamide 
Molecular Formula C6H10N2O2 
Molecular weight 142.2 g 
Melting Point 152°C 
Description White powder  
Solubility Freely soluble in water and soluble in 
alcohol.  
Storage In dry container and cool place 
 
Piracetam occurs in four different enantiometric polymorphic forms namely 
forms I, II, III and IV (Fabbiani et al., 2005) shown in Figure 5.18. The crystal 
structures of form II (triclinic) and form III (monoclinic) are known, however 
no crystallographic exploration of form I and its crystal structure has been 
reported. Form III is a commercially available most stable form whilst forms II 
and I are metastable forms.  Form II and III can be prepared by solvent 
crystallisation using various solvents such as methanol and propan-2-ol. 
Both forms convert to form I at high temperature (above 400K). Also form I 
can be prepared at room temperature by quenching the stable form, 
however, it is not stable at room temperature and within few hours 
transforms it transforms to form II. Therefore, form I is a high temperature 
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phase and has a narrow thermal stability range. The molecular confirmation 
of piracetam polymorphs are shown in figure 5.23.  
 
Figure 5.23 Conformation of piracetam molecule in different polymorphic form 
(Fabbiani et al., 2005) 
Here, form III piracetam was processed in a twin screw extruder at a 
temperature profile of T130 and screw rotation speed of 10 rpm. The 
obtained product showed a PXRD pattern which belongs to form I. This form 
I then transformed to form II after 2 weeks. Interestingly, the obtained form II 
was found to be stable for more than a year. All PXRD patterns are shown in 
figure 5.24. 
 
Figure 5.24 Experimental PXRD patterns of piracetam polymorphs 
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5.3.2. Carbamazepine 
The anticonvulsant drug, carbamazepine has been widely used for over 30 
years to treat epilepsy and trigeminal neuralgia. The P-monoclinic form has 
the lowest free energy of all the forms at room temperature. It possesses 
challenges such as a narrow therapeutic window, autoinduction of 
metabolism and dissolution dependent bioavailability (Bertilson et al., 1986). 
Carbamazepine crystallises in four anhydrous polymorphs and one hydrate. 
Many attempts have been made to improve the solubility of carbamazepine, 
such as preparing a solid dispersion, complexation or co-crystal. The 
molecular structure and physicochemical properties of carbamazepine are 
displayed in figure 5.25 and Table 5.11 respectively. 
 
Figure 5.25 Molecular structure of carbamazepine 
Table 5.11 Physicochemical properties of carbamazepine 
Chemical Name 5H-dibenzo[b,f]azepine-5-carboxamide 
Molecular Formula C15H12N2O 
Molecular weight 236.269 g/mol 
Melting Point 189-192 °C 
Description White powder  
Solubility Practically insoluble in water, slightly 
soluble in ethanol and soluble in 
chloroform  
Storage In dry container and cool place 
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Carbamazepine is known to crystallise in four anhydrous polymorphs form I 
(triclinic), form II trigonal, form III (p-monoclinic) and form IV (c-monoclinic) 
(Krahn et al., 1987). Form III is the most stable polymorph of carbamazepine 
at room temperature. There is much confusion between the naming of 
carbamazepine polymorphs in literature. Specifically, the morphologically 
similar triclinic and trigonal forms are difficult to differentiate without the use 
of PXRD. The trigonal form shows the highest free energy hence it is the 
least stable crystal form of carbamazepine.  The optimised structure of 
carbamazipne and packing diagram of carbamazepine polymorphs are 
shown in Figure 5.26.  
 
Figure 5.26 Optimised geometry of carbamazepine dimer (Adapted from 
Czernicki et al., 2013)  
 
Chapter 5: Polymorphic transformation using high temperature extrusion  
 
NOVEL FORMULATIONS OF A POORLY SOLUBLE DRUG USING THE EXTRUSION PROCESS
 Page 155 
 
 
Figure 5.27 Packing diagrams of carbamazepine polymorphs: (a) form I, (b) 
form II, (c) form III, and (d) form IV (Cambridge Crystallographic Data Centre) 
(Adapted from Czernicki et al., 2013)   
Grzesiak et al. has reported that all four form are close in energy and their 
stability order is III > I > IV > II at room temperature (Grzesiak et al., 
2003).  All polymorphs of carbamazepine share a common hydrogen 
bonding motif resulting in a dimer with two amide–amide hydrogen bonds. 
The phase transformation between these polymorphs can be induced in the 
presence of solvent or mechanical or thermal stress. It is reported that form 
III transforms to form I upon heating at 150°C for two weeks (Ceolin et al., 
1997).  
During twin screw extrusion, form III was converted to form I at a 
temperature profile of T140 and screw rotation speed of 10 rpm. Formation 
of the triclinic crystals was confirmed by PXRD (shown in figure 5.28.). Form 
III shows characteristic peaks at 2θ: 15.36, 19.56, 25.00 and 27.47 whereas 
form I shows indicative peaks at 2θ: 7.92, 9.37, 12.28 and 19.99.  
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Figure 5.28 Experimental PXRD patterns of carbamzepine polymorphs 
 
5.3.3. Chlorpropamide 
In the beginning of the 1950s sulfonyl urea therapy was introduced to treat 
type II diabetes mellitus. Chlorpropamide is one of the first generation 
sulfonyl urea derivatives offering prolonged pharmacological action. It is a 
Biopharmaceutical Classification System (BCS) class II drug which has 
solubility issues causing problems for absorption. Chlorpropamide has been 
known for its polymorphic versatility for a long time. According to the Burger 
nomenclature, the polymorphs are identified as form I, II, III, IV and V; form 
III is commercially available (Ayala et al., 2011).  Form III has the 
aforementioned solubility and stability issues. The molecular structure and 
physicochemical properties of chlorpropamide are displayed in figure 5.29 
and Table 5.12 respectively. 
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Figure 5.29 Molecular structure of chlorpropamide 
 
Table 5.12 Physicochemical properties of chlorpropamide 
Chemical Name 4-chloro-N-
(propylcarbamoyl)benzenesulfonamide 
Molecular Formula C10H13ClN2O3S
  
Molecular weight 276.74 g/mol 
Melting Point 126–130 °C 
Description White powder  
Solubility Practically insoluble in water, moderately 
soluble in chloroform and soluble in alcohol  
Storage In dry container and cool place 
 
Chlorpropamide exists in five crystal forms and has been known for its 
polymorphic flexibility for a long time. Simmon reported polymorphic 
behaviour of chlorpropamide for the first form, whilst a careful screening and 
identification of each crystal form was performed by Burger (form I, II, III, IV 
and V) (Ayala et al., 2012). Recently, Chesalov et al. anticipated a new 
nomenclature based on the order in which the crystal structures were 
elucidated. The proposed notation uses Greek characters as follows: α (III), β 
(II), γ (IV), δ (VI), and ε (I) (Chesalov et al., 2008). Form I, II and III are 
generally referred as form C, B and A.  All these forms show complex 
thermodynamic relationships and phase transformation under temperature, 
kinetic and pressure. It is often considered as a model API which undergoes 
phase transition during tabletting, the detailed mechanism of these 
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transformations has been investigated (Ayala et al., 2012). Otsuka et al. has 
reported the partial transformation of form A to C on tabletting. The density of 
form C is less than the density of form A which led to the conclusion that the 
increase in pressure during tabletting cannot account for the A to C phase 
transition (Otsuka et al., 1989). The polymorphism of chlorpropamide is a 
good case of study to demonstrate the sensitivity of Raman spectroscopy to 
conformational and packing changes. 
 
Figure 5.30 Molecular confirmations of chlorpropamide polymorphs (Adapted 
from Chesalov et al., 2008)   
Form A of chlorpropamide is commercially available (Figure 5.30) and 
considered as the most stable form whereas form C is metastable at room 
temperature and exhibits a greater dissolution rate. Form C has been known 
to generate from heating of any other crystal phase to 115°C for about 1hr 
(Ayala et al., 2012).  
Using the HTE method, commercially available form C was extruded in a 
twin screw extruder using the temperature profile T115 at a screw rotation 
speed of 10 rpm. Details of these experiments were reported earlier in 
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Chapter 3. Surprisingly, here the residence time was 10 min and complete 
transformation was achieved. This transformation was confirmed by PXRD 
(as shown in Figure 5.31).  
 
Figure 5.31 Experimental PXRD patterns of chlorpropamide polymorphs 
 
Form A exhibits characteristic peak area at 2θ: 6.6, 11.7 and 19.5 while form 
C shows a distinct peak at 2θ: 15.  
 5.3.4. Paracetamol 
Paracetamol is a para-aminophenol derivative with anti-inflammatory and 
anti-pyretic effects. It has been widely used to treat mild to moderate pain 
and fever. Though it is safe in a normal therapeutic dose, an overdose may 
cause heptic necrosis (Campanero et al., 1999). As it has a good 
toleratability profile, it is preferred in patients in whom salicylates and other 
non-steroidal anti-inflammatory drugs are contraindicated. It has a short half 
life of 2-3 hours, therefore frequent dosing is required (Coulthard et al., 
2001). Paracetamol shows three polymorphic structures: form I (monoclinic), 
form II (orthorhombic) and form III respectively. The monoclinic form of 
paracetamol is thermodynamically more stable and available in the market 
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than form II and form III. The monoclinic form has low solubility and 
processability. The molecular structure and physicochemical properties of 
paracetamol are displayed in figure 5.32 and Table 5.13 respectively. 
 
Figure 5.32 Molecular structure of paracetamol 
 
Table 5.13 Physicochemical properties of paracetamol 
Chemical Name N-(4-hydroxyphenyl)acetamide 
Mlecular Formula C8H9NO2 
Molecular weight 151.16 
Melting Point 169-172°C 
Description White, crystalline powder. 
Solubility Miscible in water  
Storage Room temperature 
 
Paracetamol crystals adapt two polymorphic structures, namely monoclinic 
and orthorhombic (as shown in Figure 5.33). The monoclinic form of 
paracetamol is the thermodynamically stable form in comparison with 
orthorhombic crystals. Although the monoclinic form is the marketed solid 
phase it has poor compressibility because it does not have slip planes in its 
crystal structure. Therefore a time consuming wet granulation process is 
generally required. In contrast, the orthorhombic form possesses a 
processing advantage; it undergoes plastic deformation during compression 
as it has well developed slip planes in its crystal structure (Martino et al., 
1996). However the orthorhombic form is metastable and offers more 
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solubility than the monoclinic form. Recently, a third form of paracetamol was 
generated in fusion experiments but this form has reported stability issues 
and therefore no data has been reported relating to its crystal structure and 
physicochemical properties.  
                            
                              A                                                   B  
Figure 5.33 The fragments of crystal structures of the two polymorphs of 
paracetamol (A) the monoclinic and (B) the orthorhombic (Adapted from 
Kolesov et al., 2011) 
The orthorhombic form of paracetamol can be obtained by solvent 
crystallisation, under pressure or thermal stress. Boldyreva et al., 
demonstrated pressure induced transformation of paracetamol. This study 
was carried out in a diamond anvil cell (Boldyreva et al., 2002). There was no 
change in a single monoclinic form crystal until pressure was increased up to 
about 4.5 GPa. Sometimes the transformation was observed when the 
pressure was slowly decreased after initial increase. Overall this 
transformation was found to exhibit poor reproducibility and depended 
strongly on the sample and on the procedure of increasing/decreasing 
pressure.    
Paracetamol was processed using HTE method at different sets of 
temperature profiles and screw speeds (details are provided in Chapter 3). 
The PXRD pattern of the monoclinic form is displayed in Figure 5.34. 
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Although paracetamol undergoes phase transformation by thermal or 
mechanical stress surprisingly no transformation was observed during the 
extrusion experiments. This requires further investigation with computational 
support to fully understand the reasons why transformation was not 
achieved; however this study is considered to be outside the scope of this 
thesis.    
 
Figure 5.34 Experimental PXRD pattern of the monoclinic form of the 
paracetamol crystal  
 
5.3.5. Theophylline 
Theophylline is a methylxanthine derivative widely used to treat asthma and 
pulmonary diseases for its bronchodilator action. Depending on the storage 
conditions, it exists in either anhydrous or in hydrous forms. Anhydrous 
theophylline exhibits three polymorphic forms: I, II and III. Form II is currently 
commercially available, has a low solubility in water and shows dose 
dependant pharmacokinetics (Parvez et al., 2004). It has a very narrow 
therapeutic range (10-20 µg/ml) and there is a very small difference between 
the therapeutic and toxic effect (Mengozzi et al., 1998). A 20-30 µg/ml serum 
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concentration of theophylline resulted in toxicity in more than 80% of 
individuals (Gohel et al., 1997). However, the efficacy and toxicity can be 
modified by applying different formulation approaches. The molecular 
structure and physicochemical properties of theophylline are displayed in 
figure 5.35 and Table 5.14 respectively. 
 
Figure 5.35 Molecular structure of theophylline 
Table 5.14 Physicochemical properties of theophylline 
Chemical Name 1,3-dimethyl-7H-purine-2,6-dione 
Molecular Formula C7H8N4O2
  
Molecular weight 180.164 g/mol 
Melting Point 270-274°C 
Description White, odourless, crystalline powder with 
a bitter taste 
Solubility Soluble in water (8.3 g/l) at 20 °C, 0.1 M 
NaOH, 0.1 M HCl, ethanol (moderately), 
DMSO, alkali hydroxides, ammonia, 
dilute hyrochloric acid, nitric acid, dilute 
aqueous acid, and dilute aqueous base. 
Storage Room temperature 
 
Three anhydrous forms of theophylline exist, namely forms I, II and III. Form 
II of theophylline is commercially used and has an orthorhombic structure. 
This form is prepared by dehydrating the monohydrate of theophylline. Form 
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I can be generated by evaporating an aqueous solution of theophylline at a 
temperature of 95°C for a period of 24 hr (Otsuka et al., 1990). Szterner et al. 
reported preparation of form I by a thermal method that involved heating form 
II in a glass vial at 110°C for 14 hr under vacuum 0.02 Pa (Szterner et al., 
2010).  
When theophylline form II was processed in a twin screw extruder using 
different temperature profiles, different intensities of shear and screw speed 
form I could not be generated. The PXRD patterns of theophylline 
polymorphs shows same peak positions but with different patterns of 
intensities. It exhibits three characteristic peaks at 2θ: 7.22, 12.7 and 14.4; 
form I shows high intensity of peak 1 and 3, and form II shows peak 2 with 
high intensity. The PXRD pattern of form II is shown in figures 5.36. This 
experiment also requires further investigation to fully understand the reasons 
why transformation could not be achieved.  
 
Figure 5.36 Experimental PXRD pattern of theophylline form II 
5.4. Summary of chapter 
HTE is a potentially commercially viable technology to induce polymorphic 
transformation under the action of high temperature and shear to obtain 
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stabilised metastable polymorphs of. Several examples have been 
demonstrated such as artemisinin, piracetam, chlorpropamide and 
carbamazepine. This method may be applicable for other pharmaceutical 
drugs where the metastable form is more efficient.  
The method involves processing of commercially available stable 
polymorphic forms using a heated screw extruder with suitable screw 
configuration at a suitable temperature either, below, above or at the melting 
point of the drug (all current examples have been processed at least 10°C 
below the melting point). Extruder screw configuration can be optimised in 
order to achieve the desired polymorph with high purity and stability. For 
example length to diameter ratio, type and level of mixing can be configured 
to achieve optimum shear conditions, temperature and residence time within 
the process. The processing temperature also plays an important role in 
achieving the desired form and purity. The obtained polymorphic form has 
been characterised and confirmed by DSC, XRPD and FTIR. Chemical purity 
was analysed using HPLC-MS. The performance was characterised using 
various studies including dissolution, pharmacokinetic and physical stability 
etc. 
This method provides a solvent free continuous route to producing stabilised 
metastable polymorph without need of any additional stabiliser. Being a 
solvent free process the instability associated with the residual solvent is 
overcome. This is a simple, continuous, reproducible, scalable process 
yielding product with high purity and stability compared to the conventional 
techniques. Moreover, the product obtained is in agglomerated form which 
reduces several unit operations in downstream processing.  
Chapter 6: Conclusion and recommended future work 
NOVEL FORMULATIONS OF A POORLY SOLUBLE DRUG USING THE EXTRUSION PROCESS
 Page 166 
 
6. Conclusion and Recommended Future Work  
As detailed in chapter 1, the primary aim of this research was to explore 
novel pharmaceutical applications of hot melt extrusion technology. Specific 
objectives included the investigation of HME to form polymeric solid 
dispersions of thermolabile drugs and an exploration of extrusion to achieve 
polymorphic transformation into more desirable forms of APIs.  This section 
lists the main conclusions drawn throughout the studies and highlights the 
most significant achievements of the work, which include enhancement of 
the physicochemical properties of artemisinin via two distinct processing 
routes. 
6.1. Conclusions 
The following conclusions summarise the most important findings drawn from 
the experimental results detailed in chapters 4 and 5: 
 Soluplus® was shown to be an effective polymer for producing an 
amorphous formulation of artemisinin by hot melt extrusion, as 
confirmed by the lack of evidence of crystalline artemisinin in DSC 
and PXRD results. Extrusion set temperature, residence time and 
screw configuration were found to be important factors which 
influenced the properties of the amorphous formulation.  
 Incompatibility between Artemisinin and Soluplus® was observed 
during rheological measurements and hot melt extrusion. Samples 
containing polymer alone did not show any discolouration whereas the 
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physical mixtures of drug and API exhibited a discolouration from 
white to yellow or brown. 
 Applied shear intensity in rheology experiments did not have a 
significant effect on the resultant colour of the amorphous formulation; 
however the colour intensity of the samples increased with increasing 
drug loading. 
 Citric acid was found to suppress degradation of the drug by 
maintaining a neutral microenvironment. Superior quality of 
artemisinin - Soluplus® solid dispersions was achieved by 
incorporating relatively low amounts of citric acid into the formulation 
prior to hot melt extrusion.  
 The optimised solid dispersion of artemisinin showed significant 
enhancement in the dissolution profile compared to the pure drug. In 
45 minutes, 92% drug was released from the solid dispersion 
(ArtSD3) which increased from 22% for pure artemisinin.  
 Comparative in-vivo pharmacokinetic studies performed in Albino rats 
using the optimised formulation (ArtSD3) and pure drug indicated a 
2.5 fold increase in Cmax and bioavailability.  
 The developed amorphous formulation of artermisinin was found to be 
stable for a period of 24 months under accelerated studies as per ICH 
guidelines. 
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 Partial polymorphic transformation from orthorhombic to triclinic 
crystals of artemisinin was observed at high temperature. This was 
found to occur during experiments through a vapour phase.  
 Under a combination of imposed shear stress and raised temperature 
the polymorphic transformation rate of artemisinin was found to 
accelerate; this was attributed to the crystalline structure being 
disrupted continuously thus exposing new surfaces. 
 The hot melt extrusion process was adapted to achieve complete 
polymorphic transformation from the orthorhombic to triclinic form of 
artemisinin. Polymorphic transformation was confirmed using PXRD, 
DSC and FTIR.  
 The prepared triclinic crystals of artemisinin significantly improved 
stability when compared to those obtained by solvent crystallisation. 
Residual solvent traces were found to affect the stability of the triclinic 
form.  
 In 10 hours 25% of artemisinin was released from the orthorhombic 
form while 90% of artemisinin was released from the triclinic form. The 
triclinic form showed a four times greater dissolution rate and two fold 
increase in bioavailability in Albino rats than the orthorhombic form.  
 Computational analysis suggested that adsorption on the triclinic {100} 
surface of artemisinin was comparable with all four of the solvents 
studied and these results were unable to explain the observed 
differences in stability of the triclinic crystals in acetone (rapid 
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conversion to the orthorhombic form) and in water (stable for more 
than 15 months). However, the transformation rate of the triclinic to 
orthorhombic form correlated well with the solubility of the triclinic form 
in each solvent.  
 Successful transformation of other APIs such as piracetam, 
chlorpropamide and carbamazepine using hot melt extrusion were 
also demonstrated.  
The key achievements of this research have been to improve the properties 
of artemisinin, an important drug in global healthcare, by two different 
extrusion based routes. A stabilised amorphous system was developed 
which demonstrated significantly improved properties over the pure API.  
Additionally a novel extrusion based process was developed to generate a 
stabilised metastable polymorph without incarporating any additional 
stabiliser. A patent application (PCT/GB/1208489.3) surrounding this 
invention has been submitted as a direct outcome of this research. 
This research has confirmed that hot melt extrusion is an attractive, solvent-
free, continuous technology which can provide significant advantages in 
commercialisation of novel pharmaceutical formulations. The high 
temperature and shearing forces encountered during extrusion can restrict 
the processing of thermolabile drugs and therefore a detailed understanding 
of the relationship between the extrusion process and material properties is 
vital. Successful processing of a thermolabile material is dependent on the 
selection of a suitable polymer and an appropriate control of the process 
parameters.   
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6.2. Recommended Future Work 
In order to gain improved understanding of the processes and formulations 
developed during this work, the following further work is recommended:  
 Developed artemisinin solid dispersion (ArtSd3) formulations can be 
suitably converted to patient compliant oral dosage form such as 
pellets, tablets and or capsules and or sachets etc. 
 Quantification of the mechanical properties of the prepared triclinic 
form of artemisnin would useful to gain further insight into the extrusion 
process.  
 In this thesis, only a single API, artemisinin, was investiaged in detail. It 
is therefore suggested that other examples would be interesting to 
study in detail. In the case of piracetam, form I is difficult to isolate as it 
transforms to form II within a few hours using traditional methods but  
form I prepared by applying the HTE technique was stable up to one 
month. Therefore a study of the solubility of form I in different solvents 
is recommended.  
 Chlorpropamide polymorphs are sensitive to Raman spectroscopy and 
therefore it is suggested that this could be used as a good example to 
apply PAT during extrusion processing. The generated form C has a 
greater dissolution rate and therefore the biovailability of the 
metastable form C could be enhanced.  
 Paracetamol and theophylline undergo polymorphic transformation 
under thermal and mechanical stress but surprisingly did not exhibit 
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phase transformation during high temperature extrusion. Further 
investigation of these examples using computational modelling is 
recommended.   
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7.3. Output  
 
Following are the output of this research work: 
 Technology for obtaining stabilized metastable polymorph, Patent 
application number: PCT/GB/1208489.3. 
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 Polymorphic transformation of artemisinin by high temperature 
extrusion 
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 Mechanism for polymorphic transformation of artemisinin during high 
temperature extrusion  
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